

UNITED STATES PATENT APPLICATION

HIGH THROUGHPUT METHODS OF HLA TYPING

Inventors: Robert Chow, a citizen of the United States of America,
residing at 1730 Wilson Avenue, Arcadia, CA 91007.

Richard Tonai, a citizen of the United States of America,
residing at 27921 Brookhaven Place, Valencia, CA 91354.

Assignee: StemCyte, Inc.
400 Rolyn Place
Arcadia, CA 91006

Entity: SMALL

HIGH THROUGHPUT METHODS OF HLA TYPING

CROSS-REFERENCES TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Patent application
5 Serial No. 60/172,768, filed on December 20, 1999, the teachings of which are herein
incorporated by reference.

FIELD OF THE INVENTION

In general, this invention relates to typing and matching human leukocyte
10 antigens or alleles of human leukocyte antigens and in particular, to high throughput
screening methods of human leukocyte antigen matching or alleles of human leukocyte
antigens.

BACKGROUND OF THE INVENTION

15 The human leukocyte antigen complex (also known as the major
histocompatibility complex) spans approximately 3.5 million base pairs on the short arm
of chromosome 6. It is divisible into 3 separate regions which contain the class I, the
class II and the class III genes. In humans, the class I HLA complex is about 2000 kb
long and contains about 20 genes. Within the class I region exist genes encoding the well
20 characterized class I MHC molecules designated HLA-A, HLA-B and HLA-C. In
addition, there are nonclassical class I genes that include HLA-E, HLA-F, HLA-G, HLA-
H, HLA-J and HLA-X as well as a new family known as MIC. The class II region
contains three genes known as the HLA-DP, HLA-DQ and HLA-DR loci. These genes
encode the α and β chains of the classical class II MHC molecules designated HLA-DR,
25 DP and DQ. In humans, nonclassical genes designated DM, DN and DO have also been
identified within class II. The class III region contains a heterogeneous collection of
more than 36 genes. Several complete components are encoded by three genes including
TNF- α and TNF- β .

Any given copy of chromosome 6 can contain many different alternative
30 versions of each of the preceding genes and thus can yield proteins with distinctly
different sequences. The loci constituting the MHC are highly polymorphic, that is, many
forms of the gene or alleles exist at each locus. Several hundred different allelic variants
of class I and class II MHC molecules have been identified in humans. However, any one

individual only expresses up to 6 different class I molecules and up to 12 different class II molecules.

5 The foregoing regions play a major role in determining whether transplanted tissue will be accepted as self (histocompatible) or rejected as foreign (histoincompatible). For instance, within the class II region, three loci *i.e.*, HLA-DR, DQ and DP are known to express functional products. Pairs of A and B genes within these three loci encode heterodimeric protein products which are multi-allelic and alloreactive. In addition, combinations of epitopes on DR and/or DQ molecules are recognized by alloreactive T cells. This reactivity has been used to define "Dw" types by cellular assays based upon the mixed lymphocyte reaction (MLR). It has been demonstrated that 10 matching of donor and recipient HLA-DR and DQ alleles prior to allogeneic transplantation has an important influence on allograft survival. Therefore, HLA-DR and DQ matching is now generally undertaken as a clinical prerequisite for renal and bone marrow transplantation as well as cord blood applications.

15 Until recently, matching has been confined to serological and cellular typing. For instance, in the microcytotoxicity test, white blood cells from the potential donor and recipient are distributed in a microtiter plate and monoclonal antibodies specific for class I and class II MHC alleles are added to different wells. Thereafter, complement is added to the wells and cytotoxicity is assessed by uptake or exclusion to various dyes by the cells. If the white blood cells express the MHC allele for a particular 20 monoclonal antibody, then the cells will be lysed on addition of complement and these dead cells will take up the dye. (*see*, Terasaki and McClelland, (1964) *Nature*, 204:998). However, serological typing is frequently problematic, due to the availability and crossreactivity of alloantisera and because live cells are required. A high degree of error and variability is also inherent in serological typing, which ultimately affects transplant 25 outcome and survival (Sasazuki *et al.*, (1998) *New England J. of Medicine* 339: 1177-1185). Therefore, DNA typing is becoming more widely used as an adjunct, or alternative, to serological tests.

Initially, the most extensively employed DNA typing method for the 30 identification of these alleles has been restriction fragment length polymorphism (RFLP) analysis. This well established method for HLA class II DNA typing suffers from a number of inherent drawbacks. RFLP typing is too time-consuming for clinical use prior to cadaveric renal transplantation for example, and for this reason it is best suited to live donor transplantation or retrospective studies. Furthermore, RFLP does not generally

detect polymorphism within the exons which encode functionally significant HLA class II epitopes, but relies upon the strong linkage between alleles-specific nucleotide sequences within these exons and restriction endonuclease recognition site distribution within surrounding, generally noncoding, DNA.

5 In addition to restriction fragment length polymorphism (PCR-RFLP), an even more popular approach has been the hybridization of PCR amplified products with sequence-specific oligonucleotide probes (PCR-SSO) to distinguish between HLA alleles (see, Tiercy *et al.*, (1990) *Blood Review* 4: 9-15). This method requires a PCR product of the HLA locus of interest be produced and then dotted onto nitrocellulose membranes or
10 strips. Then each membrane is hybridized with a sequence specific probe, washed, and then analyzed by exposure to x-ray film or by colorimetric assay depending on the method of detection. Similar to the PCR-SSP methodology, probes are made to the allelic polymorphic area responsible for the different HLA alleles. Each sample must be hybridized and probed at least 100-200 different times for a complete Class I and II
15 typing. Hybridization and detection methods for PCR-SSO typing include the use of non-radioactive labeled probes, microplate formats, etc. (see e.g., Saiki *et al.* (1989) *Proc. Natl. Acad. Sci., U.S.A.* 86: 6230-6234; Erlich *et al.* (1991) *Eur. J. Immunogenet.* 18(1-2): 33-55; Kawasaki *et al.* (1993) *Methods Enzymol.* 218:369-381), and automated large scale HLA class II typing. A common drawback to these methods, however, is the relatively long assay times needed--generally one to two days--and their relatively high complexity and resulting high cost. In addition, the necessity for sample transfers and washing steps increases the chances that small amounts of amplified DNA might be carried over between samples, creating the risk of false positives.

25 More recently, a molecular typing method using sequence specific primer amplification (PCR-SSP) has been described (see, Olerup and Zetterquist (1992) *Tissue Antigens* 39: 225-235). This PCR-SSP method is simple, useful and fast relative to PCR-SSO, since the detection step is much simpler. In PCR-SSP, allelic sequence specific primers amplify only the complementary template allele, allowing genetic variability to be detected with a high degree of resolution. This method allows determination of HLA
30 type simply by whether or not amplification products (collectively called an "amplicon") are present or absent following PCR. In PCR-SSP, detection of the amplification products is usually done by agarose gel electrophoresis followed by ethidium bromide (EtBr) staining of the gel. Unfortunately, the electrophoresis process takes a long time and is not very suitable for large number of samples, which is a problem since each

clinical sample requires testing for many potential alleles. Gel electrophoresis also is not easily adapted for automatic HLA-DNA typing.

Another HLA typing method is SSCP - Single-Stranded Conformational Polymorphism. Briefly, single stranded PCR products of the different HLA loci are run on non-denaturing Polyacrylamide Gel Electrophoresis (PAGE). The single strands will migrate to a unique location based on their base pair composition. By comparison with known standards, a typing can be deduced. It is the only method that can determine true homozygosity. However, many PAGE have to be run and many controls have to be run to make it a viable typing method. This method is very time consuming, labor intensive, and not really suited for large volume analysis.

In view of the foregoing, what is needed in the art is a method of determining genomic information from a highly polymorphic system such as the HLA class I and class II regions. The present invention provides a highly accurate and efficient HLA class I and class II sequence-based typing method that is rapid, reliable and completely automatable.

SUMMARY OF THE INVENTION

The present invention provides new and improved methods for HLA typing. In addition, the methods eliminate the reliance on agarose gel electrophoresis usage for the sequence specific primer (SSP) method for performing HLA DNA typing and obviates the reliance on using cumbersome blot membranes for sequence-specific oligonucleotide probe hybridization (SSO) as well as many of the human errors associated with manual interpretation of bands and assignment of alleles. Thus, the methods of the present invention decrease significantly the number of human errors and the amount of time and effort it takes to perform DNA HLA typing.

In certain aspects, the present invention provides a method of detecting amplified DNA in which the risks of sample cross-contamination and resulting false positive results are reduced. In addition, the present invention provides methods that can allow for reliable, rapid analysis of multiple samples. Moreover, the present invention provides a method of detecting amplified DNA that is relatively simple, and results in a relatively low cost per analysis and is amenable to automation and high throughput matching.

In one aspect, the present invention provides methods for identifying an HLA genotype of a subject. The method involves (a) obtaining a sample containing a template nucleic acid from said subject; (b) amplifying the template nucleic acid with a

plurality of HLA allele-specific forward primers and HLA allele-specific reverse primers to form amplification products, wherein the forward primers or reverse primers comprise a detectable label; (c) hybridizing the amplification products with a plurality of HLA locus-specific capture oligonucleotides immobilized on a solid phase to form a plurality of detectable complexes; and (d) detecting the detectable complexes to identify the HLA genotype of the subject.

Another aspect of the present invention provides methods for identifying an HLA genotype of a subject that involves (a) obtaining a sample containing a template nucleic acid from the subject; (b) amplifying the template nucleic acid with a plurality of HLA allele-specific forward primers and HLA allele-specific reverse primers to form amplification products, wherein the forward primers or reverse primers contain a detectable label; (c) hybridizing the amplification products with a plurality of HLA locus-specific capture oligonucleotides to form a plurality of detectable complexes; (d) immobilizing the detectable complexes on a solid phase; and (e) detecting the detectable complexes to identify the HLA genotype of the subject.

In yet another aspect of the invention, methods for identifying an HLA genotype of a subject is provided that involves: immobilizing a plurality of HLA allele-specific reverse primers on a solid phase; amplifying the template nucleic acid with a plurality of HLA allele-specific forward primers and the immobilized reverse HLA allele-specific reverse primers to form amplification products; and detecting the amplification products to identify the HLA genotype of the subject.

In certain embodiments of the present invention, template nucleic acid that is isolated from blood or cord blood is amplified. The template nucleic acid can be any gene derived sequences, including, but not limited to cDNA and genomic DNA.

In certain embodiments, oligonucleotides are immobilized on a solid phase. Examples of solid phase include, but are not limited to: a bead, a chip, a microtiter plate, a polycarbonate microtiter plate, polystyrene microtiter plate, and a slide. The methods of the present invention can be also used to determine class I and class II HLA genotypes. In certain embodiments, HLA allele-specific forward primers and HLA allele-specific reverse primers are used to amplify the template nucleic acid to generate amplification products. In some embodiments, the HLA allele-specific primers are selected from primers denoted as SEQ ID NOS:1-160 and SEQ ID NOS: 169-269.

In some embodiments of the invention, capture oligonucleotides are employed. In certain preferred embodiments, locus-specific capture oligonucleotides are used in the HLA genotyping methods and can be selected from the primers such as SEQ ID NOS: 272-277 and SEQ ID NOS:165-168. The capture oligonucleotides can be modified with a moiety that aids in immobilizing the capture oligonucleotide to a solid phase. In certain embodiments, moieties such as a 5' amine group or a 5'(T)₅₋₂₀ oligonucleotide sequence are utilized.

Detectable labels can be used with certain embodiments of the present invention. Examples of a detectable label, include, but are not limited to a radioactive moiety, a fluorescent moiety, a chemiluminescent moiety, an antigen, or a binding protein. In certain embodiments, fluorescent moieties such as fluorescein or 5-(2'-aminoethyl) aminonaphthalene-1-sulfonic acid (EDANS) are attached to oligonucleotides to facilitate detection.

These embodiments as well as additional objects and advantages will become more readily apparent when read with the accompanying figure and detailed description which follows.

DEFINITIONS

An "allele" is one of the different nucleic acid sequences of a gene at a particular locus on a chromosome. One or more genetic differences can constitute an allele. Examples of HLA allele sequences are set out in Mason and Parham (1998) *Tissue Antigens* 51: 417-66, which list HLA-A, HLA-B, and HLA-C alleles and Marsh *et al.* (1992) *Hum. Immunol.* 35:1, which list HLA Class II alleles for DRA, DRB, DQA1, DQB1, DPA1, and DPB1.

A "locus" is a discrete location on a chromosome that constitutes a gene. Exemplary loci are the class I MHC genes designated HLA-A, HLA-B and HLA-C; nonclassical class I genes including HLA-E, HLA-F, HLA-G, HLA-H, HLA-J and HLA-X, MIC; and class II genes such as HLA-DP, HLA-DQ and HLA-DR.

A method of "identifying an HLA genotype" is a method that permits the determination or assignment of one or more genetically distinct HLA genetic polymorphisms.

The term "amplifying" refers to a reaction wherein the template nucleic acid, or portions thereof, are duplicated at least once. Unless specifically stated "amplifying" may refer to arithmetic, logarithmic, or exponential amplification. The

amplification of a nucleic acid can take place using any nucleic acid amplification system, both isothermal and thermal gradient based, including but not limited to, polymerase chain reaction (PCR), reverse-transcription-polymerase chain reaction (RT-PCR), ligase chain reaction (LCR), self-sustained sequence reaction (3SR), and transcription mediated amplifications (TMA). Typical nucleic acid amplification mixtures (*e.g.*, PCR reaction mixture) include a nucleic acid template that is to be amplified, a nucleic acid polymerase, nucleic acid primer sequence(s), and nucleotide triphosphates, and a buffer containing all of the ion species required for the amplification reaction.

An “amplification product” is a single stranded or double stranded DNA or RNA or any other nucleic acid products of isothermal and thermal gradient amplification reactions that include PCR, TMA, 3SR, LCR, etc.

The phrase “template nucleic acid” refers to a nucleic acid polymer that is sought to be copied or amplified. The “template nucleic acid(s)” can be isolated or purified from a cell, tissue, animal, etc. Alternatively, the “template nucleic acid(s)” can be contained in a lysate of a cell, tissue, animal, etc. The template nucleic acid can contain genomic DNA, cDNA, plasmid DNA, etc.

An “HLA allele-specific” primer is an oligonucleotide that hybridizes to nucleic acid sequence variations that define or partially define that particular HLA allele.

An “HLA locus-specific” primer is an oligonucleotide that permits the amplification of a HLA locus sequence or that can hybridize specifically to an HLA locus.

A “forward primer” and a “reverse primer” constitute a pair of primers that can bind to a template nucleic acid and under proper amplification conditions produce an amplification product. If the forward primer is binding to the sense strand then the reverse primer is binding to antisense strand. Alternatively, if the forward primer is binding to the antisense strand then the reverse primer is binding to sense strand. In essence, the forward or reverse primer can bind to either strand as long as the other reverse or forward primer binds to the opposite strand.

The term “detectable label” refers to a moiety that is attached through covalent or non-covalent means to an oligonucleotide. A “detectable label” can be a radioactive moiety, a fluorescent moiety, a chemiluminescent moiety, etc.

The term “fluorescent label” refers to label that accepts radiant energy of one wavelength and emits radiant energy of a second wavelength.

The phrase “hybridizing” refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence or subsequence through specific binding of two nucleic acids through complementary base pairing. Hybridization typically involves the formation of hydrogen bonds between nucleotides in one nucleic acid and complementary sequences in the second nucleic acid.

The phrase “hybridizing specifically” refers to hybridizing that is carried out under stringent conditions.

The term “stringent conditions” refers to conditions under which a capture oligonucleotide, oligonucleotide or amplification product will hybridize to its target subsequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength, pH, and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. (As the target sequences are generally present in excess, at T_m, 50% of the capture oligonucleotides are occupied at equilibrium). Typically, stringent conditions will be those in which the salt concentration is at most about 0.01 to 1.0 M Na⁺ ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (*e.g.*, 10 to 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. An extensive guide to the hybridization and washing of nucleic acids is found in Tijssen (1993) *Laboratory Techniques in biochemistry and molecular biology--hybridization with nucleic acid probes parts I and II*, Elsevier, New York, and, Choo (ed) (1994) *Methods In Molecular Biology Volume 33- In Situ Hybridization Protocols Humana Press Inc.*, New Jersey; Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual* (2nd ed. 1989); *Current Protocols in Molecular Biology* (Ausubel *et al.*, eds., (1994)).

The term “complementary base pair” refers to a pair of bases (nucleotides) each in a separate nucleic acid in which each base of the pair is hydrogen

bonded to the other. A "classical" (Watson-Crick) base pair always contains one purine and one pyrimidine; adenine pairs specifically with thymine (A-T), guanine with cytosine (G-C), uracil with adenine (U-A). The two bases in a classical base pair are said to be complementary to each other.

5 "Bind(s) substantially" refers to complementary hybridization between a capture nucleic acid and a target nucleic acid and embraces minor mismatches that can be accommodated by reducing the stringency of the hybridization media to achieve the desired detection of the target polynucleotide sequence.

10 The term "capture oligonucleotide" refers to a nucleic acid sequence or nucleic acid subsequence that can hybridize to another oligonucleotide, amplification product, etc. and has the ability to be immobilized to a solid phase. A capture oligonucleotide typically hybridizes to at least a portion of an amplification product containing complementary sequences under stringent conditions.

15 A "HLA locus-specific capture oligonucleotide" is a capture oligonucleotide that is complementary to and hybridizes to a conserved region of an HLA locus. For example a "HLA locus-specific capture oligonucleotide" that is specific for the HLA-A locus will hybridize to one or more conserved regions or subsequences of the HLA-A locus.

20 A compound is "immobilized on a solid phase" when it is directly or indirectly attached to the solid phase. Such immobilization may be through covalent and/or non-covalent bonds.

25 The term "corresponding nucleotide," is used to refer to the position of a nucleotide in a first nucleic acid by reference to a second nucleic acid. Thus, a corresponding nucleotide refers to a nucleotide that it is positionally located opposite to a base where neighboring bases are all hybridized pairs.

"Subsequence" refers to a sequence of nucleic acids that comprise a part of a longer sequence of nucleic acids.

The term "portions" should similarly be viewed broadly, and would include the case where a "portion" of a DNA strand is in fact the entire strand.

30 The term "specificity" refers to the proportion of negative test results that are true negative test result. Negative test results include false positives and true negative test results.

The term "sensitivity" is meant to refer to the ability of an analytical method to detect small amounts of analyte. Thus, as used here, a more sensitive method for the detection of amplified DNA, for example, would be better able to detect small amounts of such DNA than would a less sensitive method. "Sensitivity" refers to the proportion of expected results that have a positive test result.

The term "reproducibility" as used herein refers to the general ability of an analytical procedure to give the same result when carried out repeatedly on aliquots of the same sample.

The term "amplicon" is used herein to mean a population of DNA molecules that has been produced by amplification, *e.g.*, by PCR.

The term "molecular beacon," as used herein refers to a molecule capable of participating in a specific binding reaction and whose fluorescence activity changes when the molecule participates in that binding reaction.

DETAILED DESCRIPTION

I. INTRODUCTION

The present invention provides methods for HLA genotyping of human leukocyte antigens, as well as other molecular diagnostic protocols relating to the detection of DNA sequences and sequence variations using nucleic acid amplification methods. Advantageously, the methods described herein can be used to detect genetic mutations, detect cancer gene mutations, microbial and cancer drug resistance mutations, detection of viruses, bacteria, fungi, parasites and any other microbes, forensics, parentage, *etc.*

In particular, the methods of the present invention are useful for determining HLA genotypes of samples from subjects. Such genotyping is important in the clinical arena for the diagnosis of disease, transplantation of organs, and bone marrow and cord blood applications.

In the present invention, allelic-specific HLA primers are used to amplify HLA sequences. In some embodiments, these amplification products can be immobilized to a solid phase using a locus-specific or an allele-specific capture oligonucleotide. In certain embodiments, the locus-specific capture oligonucleotides are preferred as fewer capture oligonucleotides need to be generated to carry out the HLA genotyping. In other embodiments, one HLA-specific primer is immobilized to a solid phase and the target is

amplified using another HLA-specific primer that is free in solution. The advantages and details for carrying out the present invention will be discussed more fully below.

II. MATERIALS USED IN THE PRESENT INVENTION

5 *Oligonucleotides*

Oligonucleotides used in the present invention (e.g., allele and locus-specific oligonucleotides) can be chemically synthesized according to the solid phase phosphoramidite triester method first described by Beaucage & Caruthers, (1981) *Tetrahedron Letts.* 22:1859-1862, using an automated synthesizer, as described in Van
10 Devanter *et al.*, (1984) *Nucleic Acids Res.* 12: 6159-6168. Purification of oligonucleotides is typically by either native acrylamide gel electrophoresis or by anion-exchange HPLC as described in Pearson & Reanier, (1983) *J. Chrom.* 255:137-149.

HLA allele-specific primers

15 The HLA allele-specific primers used in the present invention are designed to amplify HLA allele sequences. Since 1995, 213 class I (HLA-A, HLA-B, and HLA-C) and 256 class II (HLA-DR, HLA-DP, and HLA-DQ) alleles had been identified and sequenced (see e.g., Krausa and Browning (1996) *Detection of HLA gene polymorphism* in Browning M, McMichael A, ed. *HLA and MHC: genes, molecules and function*. Oxford: Bios Scientific Publishers Limited, pp. 113-138), with new alleles being
20 discovered all the time. The sequences of many of these alleles are publicly available through GenBank and other gene databases and have been published (see e.g., Mason and Parham (1998) *Tissue Antigens* 51: 417-66, listing HLA-A, HLA-B, and HLA-C alleles; Marsh *et al.* (1992) *Hum. Immunol.* 35:1, listing HLA Class II alleles – DRA, DRB, DQA1, DQB1, DPA1, and DPB1). Also, the use of allele-specific primers (sequence-
25 specific primers (SSP)) has permitted the specific amplification of HLA allele sequences (see e.g., Bunce and Welsh (1994) *Tissue Antigens* 43: 7-17, amplification of HLA-C alleles; Bunce *et al.* (1995) *Tissue Antigens* 46: 355-67, amplification of HLA-A.B.C. DRB1, DRB3, DRB4, DRB5 & DQB1 alleles with sequence-specific primers; Gilchrist *et al.* (1998) *Tissue Antigens* 51: 51-61, HLA-DP typing with sequence specific primers).

30 In the design of the HLA primer pairs for the primer mixes, primers were selected based on the published HLA sequences available in the literature. A chart of the HLA alleles and sequences was examined and the polymorphic sites were identified. Then pairs of primers were selected that would produce PCR products to a group of HLA alleles. The sequence specific nucleic acid amplification reaction typically uses at least a

pair of PCR primers for each allele, both of which contain the discriminating sequences with at least one or more of the changed nucleotides at the 3' end of each PCR primer. Since the 3' end is the end where polymerization takes place, if a mismatch occurs due to sequence non-complementarity, nucleic acid amplification will take place and one would not expect a "false positive." However, if a match occurs, then the amplification can proceed. For example, HLA class I allele-specific primers and HLA class II allele-specific primers are listed in Table 1 (SEQ ID NOS: 1-160) and 2 (SEQ ID NOS: 169-269), respectively. Examples of control primers listed in Table 1 are CI53 (SEQ ID NO: 161), CI54 (SEQ ID NO: 162), CI148 (SEQ ID NO: 163), and CI149 (SEQ ID NO: 164). Examples of control primers listed in Table 2 are DPA-E(PC) (SEQ ID NO: 270), and DPA-F (PC) (SEQ ID NO: 271). The Class I primers are selected to amplify Class I exon 2 and exon 3 products. The Class II primers are selected to amplify Class II exon 2 products. In certain embodiments, the primers listed in Tables 3 and 4 are used as exemplary groups of primer pairs and the HLA specificities these pairs can identify after successful positive PCR amplifications with the appropriate DNA templates for HLA class I and II alleles respectively. By utilizing a pair of primers, each PCR reaction identifies two sites of polymorphism and therefore increases the specificity of the reaction. Those of skill in the art will recognize a multitude of oligonucleotide compositions that can be used as HLA allele-specific primers to specifically amplify HLA allele sequences. In addition, customized sets of HLA-specific primers can be created to cater to detection of the allele distribution for various ethnicities or racial groups by simply changing the primer pair combinations. In this manner, detection of new alleles can be easily added to the methods of the present invention.

Capture Oligonucleotides

In certain embodiments, the invention involves locus-specific capture oligonucleotides or allele-specific capture oligonucleotides. Locus-specific oligonucleotide can hybridize to a conserved region in a HLA locus; a locus-specific capture oligonucleotide has the ability to hybridize to some or all of the sequences that can be generated by the amplification of HLA allele sequences using HLA-specific primers. Locus-specific sequences have been identified in HLA loci. For example, locus-specific sequences for HLA-class I genes have been delineated in the first and third introns flanking the polymorphic second and third exons (see e.g., Cereb *et al.* (1995) *Tissue Antigens* 45: 1-11). The capture oligonucleotides should be of such length and composition so as to be able to hybridize with the allele-specific PCR products. In certain

embodiments, HLA locus-specific class I capture oligonucleotides contain the following sequences: for HLA-A (CICptA1, Class I Capture Oligo A1, 5'ACGCCTACGACGGCAAGGATTACATCGCCC3' (SEQ ID NO:165); and CICptA2, Class I Capture Oligo A2, 5'GATGGAGCCGCGGTGGATAGAGCAGGAGGG3'(SEQ ID NO:166), for HLA-B (CICptB1, Class I Capture Oligo B1, 5'CAGTTCGTGAGGTTCGACAGCGACGCC3'(SEQ ID NO:167), and CICptB2, Class I Capture Oligo B2, 5'CTGCGCGGCTACTACAACCAGAGCGAGGCC3'(SEQ ID NO:168). In other embodiments, HLA locus-specific class II capture oligonucleotides contain the following sequences:

for HLA-DQ (DQCPT1, 5'CACGTCGCTGTCTGAAGCGCACGTACTCCTC3' (SEQ ID NO:272); DQCPT2, 5'CACGTCGCTGTCTGAAGCGGACGATCTCCTT3' (SEQ ID NO:273); DQCPT3, 5'CACGTCGCTGTCTGAAGCGTGCGTACTCCTC3' (SEQ ID NO:274); DQCPT4, 5'CACGTCGCTGTCTGAAGCGCGCGTACTCCTC3' (SEQ ID NO:275); and DQCPT5, 5'CACGTCGCTGTCTGAAGCGCACGTCCTCCTC3'(SEQ ID NO:276), for HLA-DR (DRCPT1, DRCP, 5'TGGCGTGGGCGAGGCAGGGTAACTTCTTTA3' (SEQ ID NO:277)). In certain embodiments, it may require the use of more than one capture oligonucleotide to hybridize to all of the HLA allele amplification products.

Modification of Oligonucleotides

In certain embodiments of the present invention, oligonucleotides are modified or synthesized as modified oligonucleotides to facilitate immobilization or detection.

Immobilization modifications

In certain embodiments, where capture oligonucleotides are used or where an immobilized amplification primer is used, it is desirable to modify the particular oligonucleotide to affix it to a solid phase or support. It is desired that the modification of the capture oligonucleotide does not interfere with its ability to bind to an HLA allele-specific amplification product. Those of skill in the art will recognize a variety of methods to immobilize oligonucleotides to a solid phase. For example, oligonucleotides can be directly or indirectly immobilized on a solid phase. The oligonucleotides can be immobilized directly to the solid phase through covalent and non-covalent bonds. For example, the 5' end of an oligonucleotide can be synthesized with an amine moiety (see Kawasaki *et al.* (1993)). In certain embodiments, an amine moiety with a C6 carbon spacer is conjugated to the 5' end of a capture oligo or amplification primer. The amine-

modified primers are affixed to the surface of a substrate such a Biodyne C membrane (Pall Biosupport) (Kawasaki *et al.* (1993)) or through a commercially available microtiter plate (e.g., Xenobind™ (Covalent Binding Microwell Plates), Xenopore, Hawthorne, NJ). Alternatively a polythymidine (polyT) stretch can be added to an oligonucleotide by
5 terminal deoxyribonucleotidyltransferase (Saiki *et al.* (1989)). Such a polyT stretch can be fixed to many solid substrates (e.g., nylon) using UV light leaving the rest of the oligonucleotide free to hybridize to another nucleic acid. Preferably, the polyT stretch is from 5 to 20 T's.

Alternatively, the oligonucleotides can be indirectly bound to the solid
10 phase by coating the solid phase with a substance or molecule that can bind to the oligonucleotides. Biotinylated oligonucleotides can also be used as capture oligonucleotides. Methods are known in the art for synthesizing biotinylated oligonucleotide (e.g., by synthesizing a primer with a biotinylated 5' end nucleotide as the terminal residue) (see e.g., Innis *et al.* (1990)). Biotinylated oligonucleotides can be
15 affixed to a substrate that is coated with avidin.

A high density array of capture oligonucleotides or amplification primers can be also synthesized on a substrate by attaching photoremovable groups to the surface of a substrate, exposing selected regions of the substrate to light to activate those regions, attaching a nucleic acid monomer with a photoremovable group to the
20 activated regions, and repeating the steps of activation and attachment until probes of the desired length and sequences are synthesized. (See, *e.g.*, Fodor *et al.* (1991) *Science* 251: 767-773 and U.S. Patent No. 5,143,854). The resulting array of oligonucleotides can then be used to in the methods of the present invention.

A variety of solid supports or phases can be used in the present invention.
25 Examples of solid supports include, without limitation, bead, microtiter plates, and chips. Beads can be composed of materials such as Sepharose, agarose, polystyrene, etc. and can be paramagnetic. Microtiter plates are commercially available in a variety of formats (e.g., 96, 384 and 1536 well plates) and materials (e.g., polystyrene). The plates can be either polycarbonate plates in which case the thermal gradient nucleic acid amplification
30 reaction (such as PCR) can happen directly in the well or polystyrene in which case the thermal gradient nucleic acid amplification reaction (such as PCR) has to take place in a separate polycarbonate plate and transferred to the surface modified and oligonucleotide attached plate. Isothermal nucleic acid amplification methods can be conducted in

polystyrene plates. chips can be comprised of a variety of materials, layers and substrates. Polymers which may be used as solid supports or phases include, but are not limited to, the following: polystyrene; poly(tetra)fluoroethylene (PTFE); polyvinylidenedifluoride; polycarbonate; polymethylmethacrylate; polyvinylethylene; polyethyleneimine; poly(etherether)ketone; polyoxymethylene (POM); polyvinylphenol; polylactides; polymethacrylimide (PMI); polyatkenesulfone (PAS); polypropylene; polyethylene; polyhydroxyethylmethacrylate (HEMA); polydimethylsiloxane; polyacrylamide; polyimide; and block-copolymers. The solid support on which an oligonucleotide resides may also be a combination of any of the aforementioned solid support materials.

Oligonucleotides Containing Detectable Labels

Detectable labels can also be attached to oligonucleotides to facilitate detection of the oligonucleotide in an analyte. Detectable labels can be detected either directly or indirectly, by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radiolabels (e.g., ^3H , ^{13}C , ^{14}C , ^{32}P , ^{35}S , ^{125}I , etc.), fluorescent dyes, fluorophores, fluorescent moieties, chemiluminescent moieties, electron-dense reagents, enzymes and their substrates (e.g., as commonly used in enzyme-linked immunoassays, e.g., alkaline phosphatase and horse radish peroxidase), biotin-streptavidin, digoxigenin, or haptens and proteins for which antisera or monoclonal antibodies are available. The label or detectable moiety is typically bound, either covalently, through a linker or chemical bound, or through ionic, van der Waals or hydrogen bonds to the molecule to be detected.

The detectable label should be stable to the amplifications conditions used and should permit direct or indirect detection. Indirect detection often involves the presence of one or more detection reagents. For example, one detectable label, biotin can be detected using an avidin conjugate such as avidin conjugated to an enzyme such as peroxidase (e.g., HRP), and a colorimetric substrate for peroxidase (e.g., TMB). The formation of colorimetric product can easily be detected using a spectrophotometer. For example, in certain embodiments, the primers listed in Tables 5 and 6 are biotinylated.

In certain embodiments, oligonucleotides comprising a quencher and a fluorophore moiety (molecular beacons) are contemplated. Molecular Beacons are single stranded oligonucleotide probes designed to have hairpin configuration by virtue of the presence of five to seven complementary nucleotides at their termini. The loop portion (10-40 nucleotides) is chosen so that the probe-amplification product hybrid is stable at

the annealing temperature. The length of the arm sequences (5-7 nucleotides) is chosen so that a stem is formed at the annealing temperature of the polymerase chain reaction. Also the stem or arm sequence must be designed to ensure that the two arms hybridize to each other but not to the probe sequence. One end would carry a fluorophore (e.g. 5-(2'-aminoethyl) aminonaphtalene-1-sulfonic acid (EDANS) and the other a quencher (e.g. 4-(4'-dimethylaminophenylazo)benzoic acid (DABCYL). When a probe is not hybridized to its complementary target sequence, the hairpin folding reaction would take place and fluorescence does not occur due to quenching. Quenching occurs because the energy given off as light during fluorescence is transferred to the quencher and dissipated as heat. Since the energy is released as heat instead of light, the fluorescence is said to be quenched. However, if a complementary target sequence is present, hybridization to the target sequence would be favored over the internal hairpin due to the increased stability as a result of the longer stretches of complementary sequence. The hairpin would open up thus allowing for release of quenching and the probes to fluoresce. In the fluorophore-quencher pair example given above, when stimulated by UV light with a peak wavelength of 336 nm, EDANS emits a brilliant blue fluorescence with a peak wavelength of 490 nm. (Tyagi *et al.*, (1996) *Nature Biotechnology* 14: 303-308; Tyagi *et al.* (1998) *Nature Biotechnology* 16:49-53; Paitek *et al.* (1998) *Nature Biotechnology* 16: 359-63; Kostrikis *et al.* (1998) *Science* 279:1228-1229).

III. SOURCE OF HLA GENE SEQUENCES

The template HLA DNA sequences are contained in samples containing nucleic acid (e.g., DNA, RNA, etc.), which are obtained from a biological source. In certain embodiments, the nucleic acid is isolated from a biological source containing HLA gene sequences. The nucleic acid may be from any species having HLA gene sequences, which include but are not limited to, a human, a chimpanzee, a simian, a mouse, etc. Methods are known for lysing biological samples and preparing extracts or purifying DNA, RNA, etc. See, *Current Protocols in Molecular Biology* (Ausubel *et al.*, eds., 1994)). In some embodiments, the biological source is blood, and is more preferably cord blood (e.g., blood from an umbilical cord). In methods involving cord blood or blood, two isolation procedures are preferred: Salt extraction with ethanol precipitation; and the Qiagen QIAamp® isolation method. For the salt extraction method, the cells are first lysed and centrifuged. Then water is added and the sample is centrifuged again. The pellet is digested with Proteinase K. The DNA is then extracted

by the addition of 6M Guanidine HCl and incubation at 70°C for several minutes. The sample is centrifuged again and the supernatant is precipitated with cold 95% Ethanol. The pellet is then dried and resuspended in the appropriate buffer.

RNA template sequences that are amplified using the methods and compositions of the present invention may be a single RNA template or different RNA templates. The RNA can be isolated as total RNA from a cell, bacterium, virus etc. See, Ausubel *et al.* The total RNA may be subsequently purified as poly A+ RNA or purified in a different manner to isolate certain species of interest. See Ausubel *et al.* Alternatively, the template RNA can be transcribed *in vitro* and used in the present invention. The RNA template sequence could also be reverse transcribed into cDNA and used as a nucleic acid template in the methods of the present invention.

IV. AMPLIFICATION OF HLA GENE SEQUENCES FROM NUCLEIC ACID

The methods of the present invention involve the direct or indirect detection of HLA gene sequences that have been amplified from DNA or reverse transcribed DNA. To amplify the desired nucleic acid for HLA gene sequences, the following are usually present in the reaction vessel: template nucleic acid, nucleic acid polymerase, a molar excess of dNTPs, an antisense primer(s), and a sense-primer(s), for copying a HLA gene sequence from a template nucleic acid. Preferably, the reaction can be carried out in a thermal cycler oven to facilitate incubation times at the desired temperatures.

Reaction components

Oligonucleotide Primers

The oligonucleotides that are used in the present invention, as well as oligonucleotides designed to detect amplification products, can be chemically synthesized as described above. These oligonucleotides can be labeled with radioisotopes, chemiluminescent moieties, or fluorescent moieties, etc. in a covalent or non-covalent manner. Such labels are useful for the characterization and detection of amplification products using the methods and compositions of the present invention.

Buffer

Buffers that may be employed are borate, phosphate, carbonate, barbital, Tris, etc. based buffers. See Rose *et al.*, U.S. Patent No. 5,508,178. The pH of the reaction should be maintained in the range of about 4.5 to about 9.5. See U.S. Patent No. 5,508,178. The standard buffer used in amplification reactions is a Tris based buffer

between 10 and 50 mM with a pH of around 8.3 to 8.8. See Innis *et al.* (1990). In certain embodiments of the invention, a preferred buffer for the present invention is 150 mM Tris-HCl pH 8.8 for the amplification of class I HLA sequences and 20 mM Tris HCl pH 8.8 for class II HLA sequences.

5

Salt concentration

The concentration of salt present in the reaction can affect the ability of primers to anneal to the template nucleic acid. See Innis *et al.* (1990). For example, potassium chloride can be added up to a concentration of about 50 mM to the reaction mixture to promote primer annealing. Sodium chloride can also be added to promote primer annealing. See Innis *et al.* (1990). In certain embodiments of the invention, the preferred salts are 30 mM Ammonium Chloride for class I HLA sequences and 100 mM KCl for class II sequences.

10

Magnesium ion concentration

The concentration of magnesium ion in the reaction can be critical to amplifying the desired sequence(s). See Innis *et al.* (1990). Primer annealing, strand denaturation, amplification specificity, primer-dimer formation, and enzyme activity are all examples of parameters that are affected by magnesium concentration. See Innis *et al.* (1990). Amplification reactions should contain about a 0.5 to about a 5 mM magnesium concentration excess over the concentration of dNTPs. The presence of magnesium chelators in the reaction can affect the optimal magnesium concentration. A series of amplification reactions can be carried out over a range of magnesium concentrations to determine the optimal magnesium concentration. The optimal magnesium concentration can vary depending on the nature of the template nucleic acid(s) and the primers being used, among other parameters. In certain embodiments of the invention, the preferred magnesium concentrations are 4 mM MgCl₂ and 3.4 mM MgCl₂, for class I HLA sequences and class II HLA sequences, respectively.

15

20

25

Deoxyribonucleotide Triphosphate concentration

Deoxyribonucleotide triphosphates (dNTPs) are added to the reaction to a final concentration of about 20 µM to about 300 µM. Each of the four dNTPs (G, A, C, T) should be present at equivalent concentrations. See Innis *et al.* In certain embodiments, 166 µM dNTP is the preferred concentration of nucleotides.

30

Nucleic acid polymerase

A variety of DNA dependent polymerases are commercially available that will function using the methods and compositions of the present invention. For example, *Taq* DNA Polymerase may be used to amplify template DNA sequences. Also, a reverse transcriptase can be used in certain embodiments of the present invention. Reverse transcriptases, such as the thermostable *C. therm* polymerase from Roche, are also widely available on a commercial basis.

Other agents

Assorted other agents or compounds are sometime added to the reaction to achieve the desired results. For example, DMSO can be added to the reaction, but is reported to inhibit the activity of *Taq* DNA Polymerase. However, DMSO has been recommended for the amplification of multiple template sequences in the same reaction. See Innis *et al.* Stabilizing agents such as gelatin, bovine serum albumin, and non-ionic detergents (e.g. Tween-20) are commonly added to amplification reactions. See Innis *et al.* For the amplification of class II sequences, the addition of 0.2% Triton X-100 has been found to be preferred. In addition, to enhance specificity by decreasing spurious priming, methods that incorporate "hot start" (e.g., AmpliWax® (Applied Biosystems, Inc.), or an monoclonal antibody to *Taq* polymerase (CLONTECH Laboratories, Inc.) can be used to increase the specificity of an amplification reaction.

Amplification Programs

To amplify the HLA gene sequences of interest, the amplification reaction mixture is subjected to a series of temperatures to repeatedly denature the nucleic acid, anneal the oligonucleotide primers, and extend the primers with the polymerase. The use of a thermal cycling device can greatly facilitate the temperature cycling required in certain embodiments of the present invention. The optimum denaturing, annealing and extending temperatures can be determined by one of skill in the art for a particular oligonucleotide primer pair(s) and HLA gene template(s). In general, the extension step is carried out at a temperature of about 72 °C and the denaturing step is carried out at about 96 °C. In addition, it may be necessary to carry out different sets of amplification cycles in succession to achieve the desired results. In addition, the number of cycles is an important consideration. Typically, one of skill in the art can carry out experiments to determine what is the optimum number of cycles to amplify the desired template(s).

The annealing temperature is of critical importance in any amplification reaction. If the annealing temperature is too low, non-specific amplification of undesired templates can arise. If the annealing temperature is too high, the template may not be efficiently amplified if at all. Determining the optimum annealing temperature for in reactions that involve large numbers of different oligonucleotide sequences and HLA templates is particularly important. A preferred amplification program for amplifying template HLA gene sequences where both primers are in solution is the following 6-stage program:

- 1.) 1 Cycle 97 °C for 20 seconds
- 2.) 5 Cycles 97 °C for 35 seconds, 61 °C for 45 seconds, 72 °C for 40 seconds
- 3.) 25 Cycles 97 °C for 20 seconds, 59 °C for 45 seconds, 72 °C for 40 seconds
- 4.) 4 Cycles 97 °C for 20 seconds, 57 °C for 45 seconds, 72 °C for 90 seconds
- 5.) 1 Cycle 72 °C for 4 minutes
- 6.) 1 Cycle 30 °C for 1 second.

A number of controls can be used in the amplification methods described herein. They include, but are not limited to: 1. Omission of Primers - Control of spurious priming; 2. Known negative control - Control of specificity; 3. Known positive control - Control of sensitivity; 4. Omission of DNA Polymerase - Detection of nonspecific probe and/or enzyme/antibody sticking; 5. Use of irrelevant probes for hybridization - Control for hybridization; 6. Amplification of endogenous control DNA sequence - Detection of false negatives, control of DNA/RNA quality.

V. WASHING

After a hybridization step or after solid-phase PCR (e.g., amplification with an immobilized primer), a solid phase can be washed with a buffer to decrease non-specific binding, to wash away unbound primers, or to provide a solution that is more appropriate for subsequent detection of a detectable label, etc. Where an oligonucleotide has been immobilized or hybridized to an oligonucleotide on a solid support, the unbound oligonucleotides can be washed from a bound complex using variety of separation methods known in the art. There are many separation methods known in the art (e.g., filtering, sedimenting, centrifuging, decanting, precipitation, etc.) that can be used or adapted for use in the present invention. For example, where the amplification product is immobilized on a microtiter plate, the unbound oligonucleotides can be aspirated from the well, leaving behind those amplification products, HLA allele sequences, etc. that are

bound to a solid phase. Another separation method is the immobilization of an amplification product, HLA allele sequence, etc. on a paramagnetic bead, and the decantation or aspiration of the unbound primers and oligonucleotides leaving behind the bound complex containing a detectable label remaining on the solid phase. Commercial
5 kits, methods and systems are commercially available and can be adapted or used with the present invention (e.g., the KingFisher™ system from Thermo Labsystems, Inc.).

A wash buffer can contain a detergent, or other agents, and compositions that are compatible with retention of the bound complex on the solid phase. A blocking agent is generally present in the wash buffer. Blocking agents include, but are not limited
10 to non-fat dry milk, herring sperm DNA, dextran sulfate, and BSA. For example, a wash buffer that can be used in the present invention is a solution of 0.1 % BSA in PBS. The use of 0.1 % BSA results in optimum results. One or more washes may be necessary to achieve optimum lowering of non-specific binding.

45 VI. DETECTION

A wide range of methods can be used to detect the presence of oligonucleotides that contain a detectable label. The method of detection depends on the nature of the detectable label that is present. If the label is directly or indirectly capable of generating a signal in the visible light range, then a spectrophotometer can be used.
20 Similarly, a fluorescent detectable label or signal generated therefrom can be measured using a fluorescent spectrophotometer. Alternatively, luminometers can be used to measure chemiluminescent signals. Isotopic labels can be measured using a liquid scintillation counter or in some cases – x-ray film. In certain embodiments, it is preferred to use a spectrophotometric plate reader that can read microtiter plates in an automated
25 system.

VII. ANALYSIS OF RESULTS OF ASSAYS

Computer programs containing algorithm(s) can be used to score, interpret and assign HLA alleles in certain embodiments of the present invention. Briefly, the data
30 from a detection instrument (e.g., a spectrophotometer, an ELISA reader, a scintillation counter, etc.) can be analyzed through the use of a computer program that compares the values of each sample against a reference value(s).

For example, computer programs for the ELISA format readers take readings below a designated threshold and label such as negative and values above the

same thresholds as positives. A positive well or a combination of certain wells would then represent a specific gene sequence or allele and be scored as such with the automated program. The optical density (O.D.) values obtained from reading of the wells of the ELISA plate readers are given as numerical values ranging from 0.000-2.000. This information is automatically downloaded onto the attached computers via the vendor provided software. The O.D. values are saved in a spreadsheet format in the vendor provided program as raw data.

The first step in computer analysis of the data is to validate and assign the negative control reading from the negative control well, which always exists in the same well location on the plate. A properly performed negative control is assigned as the negative value. In some embodiments where peroxidase is used with TMB, negative controls are deemed properly performed when the O.D. values are below 0.2. The usual O.D. values of a negative control reaction yielding colorless products are usually between 0.05 and 0.1. Then the threshold level is determined for that particular reaction to be 3.5 times the value of the negative control. A well is considered weakly positive if the reaction yields an O.D. reading that exceeds 3.0-fold but is below 3.5-fold of the negative control reading. A weakly positive well is rejected if two other strongly positive alleles are present for that locus. In the absence of two other strongly positive alleles for each locus, the weakly positive well is accepted if it is confirmed with repeat testing or alternative methods. A truly positive well is assigned when the O.D. readings exceed 3.5-fold over the value of the negative control. The computer program analyzes the results of all the wells, determines the positive wells based on the established criteria, and assigns the alleles based on which primer pairs exist in the positive wells. If more than two alleles are identified per locus, then the results have to be analyzed using the following protocol and confirmed by repeat testing or alternative methods.

By storing numerical reading values for the various primer pairs, many different type of assessment are possible. For example, the effects of the changes in primer pairs and primer sequences on average O.D. readings can be assessed. Consistently weak reacting sets can be replaced with primer pairs giving more robust and consistent results. Alternatively, if a particular weak reacting set of primers have no substitute, then handicap scores can be given. A more consistent tray can be developed by using the reading values as a point of reference.

VIII. HIGH THROUGHPUT METHODS AND SYSTEMS.

In the present invention, high-throughput analysis of HLA genotypes can be performed using automated devices. For example, an automated workstation (see e.g., U.S. Patent No. 5,139,744, "Automated laboratory workstation having module
5 identification means") can be used to perform many of the steps involved in the present invention. An "automated workstation" is typically a computer-controlled apparatus which can, through robotic functions, transfer, mix, and remove liquids from microtiter plates. An automated workstation can also contain a built-in plate reader, which can read the absorbance of a liquid in a microtiter well. The automated workstation can be
10 programmed to carry out a series of mixing, transfer, and/or removal steps. The automated workstation will typically have a multi-channel pipettor which can pipette small amounts of liquid (e.g., microliter amounts) from a vessel to the well.

For example, in some embodiments of the present invention, the automated workstation can be used to transfer DNA samples, oligonucleotides,
15 amplification reagents. The automated work station can also be used to wash the samples using wash buffer. In addition, detection of oligonucleotides containing a detectable label can be carried out using an automated workstation. For example, the automated workstation can be used to add a detection reagent to the wells. The automated workstation, when equipped with a plate reader, can monitor the absorbance of the
20 reaction of the detection reagent in the wells.

A number of robotic fluid transfer systems/automated work stations are available, or can easily be made from existing components. For example, a Zymate XP (Zymark Corporation; Hopkinton, MA) automated robot using a Microlab 2200 (Hamilton; Reno, NV) pipetting station can be used to transfer parallel samples to 96 well
25 microtiter plates to set up several parallel simultaneous ligation reactions. Other automatic microplate dispensers include Lambda Jet and Lambda Dot (One Lambda, Inc. CA), and various other automatic plate washers and dispensers (e.g. from Thermo Labsystems, Inc. or Molecular Devices, Inc.). Moreover, it will be apparent to those of skill in the art that the PCR setup, reagent addition and washing steps can be automated
30 with existing robotics outlined above.

Optical images viewed (and, optionally, recorded) by a camera or other recording device (e.g., a photodiode and data storage device) are optionally further processed in any of the embodiments herein, e.g., by digitizing the image and storing

and analyzing the image on a computer. A variety of commercially available peripheral equipment and software is available for digitizing, storing and analyzing a digitized video or digitized optical image, *e.g.*, using PC (Intel x86 or Pentium chip- compatible DOS OS2 WINDOWS, WINDOWS NT or WINDOWS 98 based machines),

- 5 MACINTOSH, or UNIX based (*e.g.*, SUN work station) computers.

One conventional system carries light from the specimen field to a cooled charge-coupled device (CCD) camera, in common use in the art. A CCD camera includes an array of picture elements (pixels). The light from the specimen is imaged on the CCD. Particular pixels corresponding to regions of the specimen (*e.g.*, individual hybridization sites on an array of biological polymers) are sampled to obtain light intensity readings for each position. Multiple pixels are processed in parallel to increase speed. The apparatus and methods of the invention are easily used for viewing any sample, *e.g.*, by fluorescent or dark field microscopic techniques. The use of such automated machines, can minimize the existence of false positives, labor requirements, variabilities, human errors, human subjectivity, and human expertise requirements, and maximizes throughput, accuracy, sensitivity and specificity.

IX. HYBRIDIZATION OF CAPTURE OLIGONUCLEOTIDES TO HLA AMPLIFICATION PRODUCTS

Hybridization of Immobilized Capture Oligonucleotides to HLA Amplification Products

This method involves the use of immobilized oligonucleotides to capture HLA allele sequences contained in an amplification product. Briefly, HLA allele sequences are amplified from a template nucleic acid using HLA allele-specific forward and reverse primers. One or both of the amplification primers can contain a detectable label. Then the amplification products are denatured and hybridized to a locus-specific or allele-specific capture oligonucleotide that is already immobilized to a solid phase to form a detectable complex. The presence of the detectable label in the detectable complex is then measured using methods known to those of skill in the art (*e.g.*, spectrophotometric means, a luminometer, etc.), which may require the addition of one or more detection reagents (*e.g.*, an avidin-enzyme molecule with a colorimetric enzyme substrate).

The capture oligonucleotides possess sufficient nucleotide complementarity to the HLA allele sequences being amplified that they can hybridize to

them under stringent conditions. Typically, the HLA allele-specific forward and/or reverse primer will contain a detectable label (e.g., biotin, digoxigenin, EDANS, or a fluorescent moiety, etc.) so as to facilitate detection. Thus, this method allows for the amplification of many different HLA alleles which can be detected with, in the case of some HLA loci, as little as one capture oligonucleotide that is locus-specific. This is an advantage over previous methods, in which allele-specific capture oligonucleotides were used, as the detection of hundreds of alleles would require hundreds of allele-specific capture oligonucleotides (see e.g., Erlich *et al.* (1991) *Eur. J. Immunogenet.* 18(1-2): 33-55; Kawasaki *et al.* (1993) *Methods Enzymol.* 218:369-381). Thus, the present invention permits a great simplification and reduction in the number of oligonucleotides required to detect hundreds of HLA-alleles.

Hybridization of Free Capture Oligonucleotides to HLA Amplification Products and Subsequent Immobilization of the Detectable Complex.

In another embodiment of the present invention, the hybridization takes place in solution with capture oligonucleotide(s) and then the capture oligonucleotide is immobilized. This method involves the use of capture oligonucleotides that are hybridized in solution to HLA allele sequences contained in an amplification product and subsequent immobilization of the capture oligonucleotide to a solid phase. First, HLA allele sequences are amplified from a nucleic acid using HLA allele-specific forward and reverse primers. Then the amplification product are denatured and hybridized to a locus-specific or allele-specific capture oligonucleotide that is already immobilized to a solid phase. The capture oligonucleotides then hybridize and bind to the denatured single stranded PCR products at a suitable hybridization temperature and "capture" complementary sequences in the products onto the plate. If none or very little complementary sequences for the capture oligonucleotide are present after the nucleic acid amplification reaction (for example, if the allele sequence represented by the allele-specific PCR primers are not present in the sample DNA template, then no PCR product would be formed), then it is unlikely a detectable complex will form. The capture oligonucleotides possess sufficient nucleotide complementarity to the HLA allele sequences being amplified that they can hybridize to them under stringent conditions. Typically, the HLA allele-specific forward and/or reverse primer will contain a detectable

label (e.g., biotin, digoxigenin, EDANS, or a fluorescent moiety, etc.) so as to facilitate detection.

In this method, capture oligonucleotides with either conserved sequences (e.g., locus-specific oligonucleotides) or allele specific sequences can be used. The later offering an additional level of specificity whereas the former offers convenience and ease of setup as well as lower cost in having fewer sets of oligonucleotides. Thus, this method allows for the amplification of many different HLA alleles which can be detected with, in the case of some HLA loci, as little as one capture oligonucleotide that is locus-specific. This is an advantage over previous methods, in which allele-specific capture oligonucleotides were hybridized in solution to a locus-specific HLA amplification product, as the detection of hundreds of alleles would require hundreds of allele-specific capture oligonucleotides (see e.g., Nevinny-Stickel and Albert (1993) *Eur. J. of Immunogenet.*, 20: 419-427). Thus, the present invention permits a great simplification and reduction in the number of oligonucleotides required to detect hundreds of HLA-alleles.

X. AMPLIFICATION OF HLA SEQUENCES WITH IMMOBILIZED PRIMERS

This method involves the amplification of HLA sequences using allele-specific primers, where one of the pair of amplification primers is immobilized to a solid phase. The other primer constituting the primer pair contains a detectable label and is initially free in solution. This technique is not limited to the detection of HLA alleles. Essentially, any set of amplification primers and any gene can be amplified. With this method, the immobilized amplification primer serves to immobilize the amplification product directly to a solid phase. The amplification should only take place if allele that can be amplified with a particular pair of allele-specific primers is present in solution.

The nucleic acid amplification and capture of PCR product take place on the same polycarbonate plate and the capture oligonucleotide/PCR primer is an allele specific sequence that identifies the sequence of interest (e.g. the particular HLA allele) and serves three purposes. First, it serves as the capture oligonucleotide and immobilizes the PCR products onto the plates. Second, it serves as one of the PCR primers that facilitate the nucleic acid amplification reaction. Third, it serves as the discriminating sequence that allows identification of the correct allele. This means that the PCR amplification reaction would only take place if the correct sequences that is perfectly complementary to the template (which is the particular allele of the person whose HLA sequence or other

sequence is being typed) is present on both PCR primers. An advantage of this method is the elimination of transfer, reduction of an additional set of oligonucleotides to the assay vessel (compared with two previous methods described under Section X).

If a sequence specific nucleic acid amplification reaction occurred due to perfect matching between the PCR primers and the template sequences, then the product would be immobilized on the solid phase. Following capture, the unbound non-specific labeled PCR primers can be washed off. With fluorescent probes, the plate can be read with an automated fluorescent ELISA format reader. With colorimetric reactions that are associated for example with avidin conjugated enzyme and substrate systems (e.g. avidin-conjugated horseradish peroxidase and TMB), a photometric ELISA format reader would be able to quantitate the result.

XI. MULTIPLEXING OF POSITIVE CONTROLS

In certain embodiments, one or more positive control can be added to each reaction vessel. For example, a positive control in every well can be used to distinguish from the allele specific reactions by virtue of having a different fluorophore or enzyme-substrate combinations. For example, if the allele specific reaction and the positive control use different fluorophores, then the excitation and emission wavelengths for both fluorophores can be used. The positive control amplified fragment would be longer than the allele specific reaction so that the allele specific reaction would be favored. The positive controls would be captured by the same capture probe as the allele specific if the capture probe is locus-specific. If allele-specific capture probes are used, then the positive controls may have complementary sequences to the allele specific capture probes at its 5' end of the primer that is labeled.

XII. MAGNETIC BEAD VARIATION

This method takes advantage of a commercially available nucleic acid purification method that employs magnetic beads coated with avidin or other materials to facilitate the "fishing" of the appropriate nucleic acid product of interest (KINGFISHER™ available from Thermo Labsystems, Inc.). For example, if biotinylated oligonucleotide PCR primers are used, then a biotinylated PCR product will be captured with the avidin on the beads. The magnetic beads are then pulled out of the reaction well, washed and all non-biotinylated materials will be washed off. The biotinylated products and primers are then separated from avidin coated beads by further treatment, such as

elution with excess free biotin. Thereafter, the biotinylated products are hybridized to the capture probe of interest and separated from the biotinylated primers. Alternatively, a labeled hybridization probe is allowed to bind to the PCR product, followed by washing using the KINGFISHER™ method to remove any unbound non-specific signals. Lastly, the signals would be measured. Instead of biotinylated beads, covalently modified beads that attach to PCR oligonucleotides can also be used.

XIII. SSOP WITH MOLECULAR BEACON DETECTION

In the methods of the present invention, molecular beacon oligonucleotides can be used to hybridize with allele-specific amplification products. Once the modular beacons are hybridized to a complementary sequence in an amplified product, the quencher group is no longer close enough to quench the fluorophore. As a consequence the fluorophore can be detected and quantitated. These molecular beacon oligonucleotides are known in the art and can be readily designed (see Materials section on design and construction of molecular beacon oligonucleotides). These oligonucleotides have the advantage of being directly assayable with a device that can measure fluorescence. In addition, this method can exhibit lower background signal than other methods as only oligonucleotides that are incorporated into an allele-specific product will give off a signal. Thus, molecular beacon detection does not require the addition of a detection reagent to observe whether an HLA genotype is present in an analyte.

XIV. IN SITU AMPLIFICATION VARIATION

In certain embodiments, the *in situ* amplification method is chosen to eliminate the need for DNA extraction and preparation. In contrast to the usual limitations of *in situ* amplification where the number of cycles has to be curtailed to prevent the floating away of amplified products from the cell, it is irrelevant whether amplified product stays in the cell or out. As a result, the same number of cycles can be used to generate the same degree of amplification as traditional PCR. If molecular beacon method is not incorporated into the protocol, then the reaction products from the wells will be transferred to another microtiter plate that has surface attached capture oligonucleotide probes that are similar to the ones described earlier with either conserved sequences which can be used in all the wells or allele specific sequences. By using an *in situ* amplification method it is then possible to use molecular beacons to detect the amplified products. *In situ* amplification can be carried out on a microscopic slide, a tissue sample, a microtiter plate, etc.

The molecular beacon method can be incorporated to eliminate even the washing step as well as the need for specially modified plates that can be quite expensive. It also allows for real time measurement of PCR product formation. When PCR products are formed and denatured during the various cycling steps, molecular beacons would hybridize to some of the complementary single strands, thereby fluorescing and allowing real time measurement. If real time measurement is not desired, then the molecular beacon probe can be added at the end of the reaction and only wells with amplified products that are complementary to the molecular beacon would light up. Because the unbound molecular beacon does not fluoresce, washing steps may not be necessary if the signal to noise ratio is high enough.


XV. TISSUE BLOCK SECTION VARIATION

The methods of the present invention can be carried out on paraffin embedded formaldehyde fixed sections of buffy coats, umbilical cord blood clots or blood clots placed onto glass slides with grids. The same sample can be placed onto one slide and different probes are used in an *in situ* method or many samples can be placed onto the same slide and the same probe is used for all the samples. In the latter, as many sections and slides of the samples will be cut as the number of probes plus controls. This method appears to be easier for the amplification, since there is no need to separate the different probes or reactions from one another.

EXAMPLES

EXAMPLE 1 -DETECTION OF HLA ALLELES WITH PRE-IMMOBILIZED HLA LOCUS-SPECIFIC CAPTURE OLIGONUCLEOTIDES

As a first step, experiments were carried out to determine what are the optimum conditions for immobilizing a capture oligonucleotide to a plate. In this experiment, Capture Oligonucleotide1 (5'ACCGCACCCGCTCCGTCCCATTGAAGAAAT²⁷⁶) was modified with an amine at the 5' end with a C6 linker and a biotin group on the 3' end. For the purpose of actual HLA genotyping, the Capture Oligonucleotide will not have a biotinylated 3' end. The oligonucleotide1 was incubated on a 96 well Covalent Binding Microwell plate (Xenobind™, Xenopore, Hawthorne, NJ) according to the manufacturer's instructions.

Cont
a' 

The plate was then washed three times with phosphate-buffered-saline (PBS). ExtrAvidin® Peroxidase (SIGMA) was added and allowed to incubate on the tray. The plate was washed three times with PBS. TMB substrate (3,3',5,5' - Tetramethylbenzidine) was added to the plate, 1N HCl added and tray was read at 450 nm. The current optimum conditions for oligonucleotide binding was Capture Oligonucleotide at 100 ng/ul in PBS at pH 8.8 incubated overnight at 4°C. Alternatively, binding can occur at 37 °C for 2 hours with Capture Oligonucleotide at 100 ng/ul in PBS at pH 8.8.

Amplification of HLA alleles was carried out on DNA extracted from cord blood from three donors: Sample #8, Sample #12, and Sample #18. Purification of the DNA was carried out using either the Salt extraction with ethanol precipitation method or the Qiagen QIAamp® isolation method. The amplification was carried out using oligonucleotide primers designed to hybridize to alleles in the HLA A, B, C loci for Class I and HLA DR and DQ for Class II. The sequences and location of these primers are given in Tables 1 & 2. For Examples 1, 2, and 3, the primers listed in Tables 5 and 6 were biotinylated.

All primers are adjusted to their optimum concentration of 100 ng/ul. Primer pair mixes were set up to aliquot into PCR trays. Two different 96 well trays are set up see Tables 3 & 4. The mixes are aliquoted into labeled 1.2 ml according to the volumes given in Tables 3 & 4.

A 96 well tray dotting machine was utilized to dot the PCR Trays. The polypropylene trays are labeled with their tray identification, i.e., Class I tray and dotting number. 200 trays can be dotted with each 1.1ml Primer Mix set. The 96 well dotting machine was adjusted to a draw volume of 250 ul and a dispense volume of 5 ul. Fifty 96 well trays at a time can be dotted. Once the primers are dotted 17.0 ul of mineral oil was added to each well. The PCR tray was then covered with adhesive tape. The trays are then boxed and stored at -20 °C until use.

HLA allele sequence amplification was accomplished by adding the DNA mixture to the PCR tray and placing the tray in a thermal cycling oven. The DNA mixture contains: 40.0 ul of DNA (50-100 ng/ul), 4.0 ul Taq polymerase (5 U/ul), and 600.0 ul PCR Mix into a labeled 1.5ml tube. For Class I HLA trays, the PCR mix contains 30 mM Ammonium Chloride, 150 mM Tris-HCl pH 8.8, 4 mM MgCl₂, and 166 uM dNTP. For Class II HLA trays, the PCR mix contains 100 mM KCl, 20 mM Tris HCl pH 8.8, 0.2% Triton X-100, 3.4 mM MgCl₂, and 166 uM dNTP.

A liquid sample dispensing machine was used to add the DNA mixture to tray PCR tray. The 250 ul dispensing syringe was employed. The machine was set to add 5.0 ul to a 96 well microtiter tray. The appropriate PCR tray was placed in the machine. The DNA mixture was vortexed and then 5.0 ul of DNA mixture was dispensed into each of the 96 wells of the PCR tray. The tray was then placed in the thermal cycling oven (BioOVen, BioTherm™ Products, MD). The PCR was carried out in the cycling oven in the following 6 stage program:

- 1.) 1 Cycle 97 °C for 20 seconds
- 2.) 5 Cycles 97 °C for 35 seconds, 61 °C for 45 seconds, 72 °C for 40 seconds
- 3.) 25 Cycles 97 °C for 20 seconds, 59 °C for 45 seconds, 72 °C for 40 seconds
- 4.) 4 Cycles 97 °C for 20 seconds, 57 °C for 45 seconds, 72 °C for 90 seconds
- 5.) 1 Cycle 72 °C for 4 minutes
- 6.) 1 Cycle 30 °C for 1 second

This 6-stage program generates the optimum PCR amplification profile for this example. After amplification, PCR product was diluted. A dilution of 1:10 with PBS pH 7.4 was optimum. Therefore, 90 ul of PBS pH 7.4 was added to the PCR product. 50.0 ul of diluted PCR product was transferred from the PCR tray to the Capture plate using the 96 well dotting machine. The machine was adjusted to draw and dispense 50.0 ul.

The capture tray was then placed in the thermal cycling oven and the one stage Capture Program was run. The Capture program for this example was as follows: 1 Cycle of 97 °C for 6 minutes, 57 °C for 12 minutes, and 30 °C for 1 second. 100 ul of hybridization solution (PBS at pH 7.4) was added to the capture tray. Also a hybridization solution of 0.9 M NaCl, 90 mM sodium citrate, 1 mM EDTA, 0.1% Ficoll, 0.3% BSA, 0.5% SDS can be used. The tray was incubated at 45 °C for 120 minutes. After the hybridization incubation the capture plate was washed. Using the plate washer, the capture plate was rinsed three times with 200 ul PBS pH 7.4 in each well.

For detection, ExtrAvidin® Peroxidase was diluted 1:2000 in 4% BSA in PBS pH 7.4, and 50.0 ul was added to each well. The Capture tray was incubated at 37 °C for 30 minutes. Then the Capture tray was washed four times with 200 ul PBS pH 7.4 in each well by the plate washer. 50.0 ul of liquid substrate (3,3',5,5' - Tetramethylbenzidine) was added to each well and incubated at 37 °C for 30 minutes. 50.0 ul of 1N HCl was added to each well to stop the reaction. The trays are read on the

Plate reader by setting the filter to 450 nm. The plate configuration was set to default a 96 well Flat bottom microtiter plate.

Data readings are stored as a spreadsheet file. Positive reactions are identified by values over threshold. Threshold was determined by numerical values that are at least 3.5 times over the value of the negative control and the average of the negative reaction values. HLA typing results are determined by the specificity corresponding to the positive reactions. The genotypes were determined as follows:

Sample #8 A*0201,A*2402, B*0701, B*3501 C*0401, DRB1*0101,DRB1*1501
DRB5*0101: Sample #12, A*0201, B*1301, B*4402, C*0601 DRB1*0403,
DRB1*1401 DRB3*0101,DRB4*0101; and Sample #18 A*0101,A*1101
B*0801,B*1801, C*0701, DRB1*0901, DRB1*1403, DRB3*0301, DRB4*0101.

EXAMPLE 2 SIMULTANEOUS HYBRIDIZATION OF CAPTURE OLIGONUCLEOTIDE TO DENATURED PCR PRODUCT TO CAPTURE PLATE.

For this example, a modification of the method carried out in Example 1 was performed. In this example, the amplification product is hybridized to a capture oligonucleotide(s) in solution. The capture oligonucleotide is then immobilized on a solid phase. The complexes are washed and a detection step is then performed.

The set-up of the PCR Tray was carried out as in Example 1. The PCR amplification was carried out as in Example 1 on DNA from donors #8, #12, and #18. The DNA was purified as in Example 1. After PCR amplification, diluted capture oligonucleotide was added to the wells: 5.0 ul of capture oligonucleotide at a concentration of 50 ng/ul was added to each well. The tray was placed in a thermal cycling oven and subjected to the following capture program: 1 Cycle of 97 °C for 20 seconds, 57 °C for 60 seconds, and 30 °C for 1 second. After the capture program is run, the PCR products are now hybridized with the capture oligonucleotide. The hybridized PCR products are diluted. A dilution of 1:10 with PBS at pH 7.4 was optimum. 90.0 ul of PBS at pH 7.4 was added to each well in the PCR tray. 15.0 ul of the diluted PCR product was transferred by the 96 well dotting machine into a new covalent binding plate (Xenobind™) containing 50.0 ul of PBS at pH 7.4 in each well. The plate was incubated overnight at room temperature so that the hybridized PCR product with the capture oligonucleotide with its amine linker at the 5' end can bind to the plate.

Using the plate washer, the plate was washed twice with 0.1% BSA in PBS at pH 7.4. ExtrAvidin® Peroxidase conjugate was diluted 1:2000 in 4% BSA in

PBS at pH 7.4, and 50.0 ul was added to each well. The plate was incubated at 37 °C for 30 minutes and then washed six times with 200 ul of PBS pH 7.4 in each well by the plate washer. 50.0 ul of liquid substrate (3,3',5,5' – Tetramethylbenzidine) was added to each well and incubated at 37 °C for 30 minutes. 50.0 ul of 1N HCl was added to each well to stop the reaction. The Tray reading was carried out as in Example 1. The Analysis is carried out as in Example 1.

Four basic results were observed. A "Good" result was assigned if the value for the negative control was the same as the value of a negative allele specific primer pair. Also the value of the positive control had to be higher than the value of the negative control by a factor of at least 3.5. Furthermore, the value of all positive wells had to be 3.5 times greater than the negative wells. A "Weak" result was assigned if the signal to noise ratio is above three fold but less than the 3.5 fold necessary for comfortable discrimination between positive reactions and negative reactions. Results were identified as "Too Positive" or "Background" if the value of the negative control was within acceptable limits but some of the negative wells have values equal or above that of the positive control wells. Results of "Too Positive" were observed when the Avidin conjugate concentration was too high or if insufficient washing was performed or if there was PCR DNA contamination. An "All Negative" result would be assigned if the values of the all wells were similar to the value of the negative control well. Results of "All negative" were observed when hybridization temperatures were too stringent (above 45 °C) or if the hybridization incubation times were too short (less than one hour) or if the washing conditions were too vigorous. Dilution and washing conditions are important factors to obtain the best conditions. If the hybridization product was not diluted enough, non-specific binding would result in false positives. If the washes were not exhaustive enough, false positive results would be observed.

The use of the automatic plate washer eliminated the inconsistent results and false positives that results from accidental PCR product contamination that manual handling produces. Once the washer was employed, false positive reactions and false negative reactions were greatly reduced. This observation is most likely and logically attributed to the elimination of carryover and inconsistent washing that occurs with manual washing.

In parallel with the procedure just carried out, PCR-SSP was performed using the same primer pair sets and amplification conditions. Briefly, PCR-SSP was performed with the primers sets described and the amplification products were run on

agarose gels. The bands on the gel identified the positive reactions and a typing was obtained based on the positive reactions.

The allele assignments of donors #8, #12, and #18 using the PCR-SSP method and the inventive method of this example are given below:

Summary of Typing Results

Sample #8:

PCR-SSP: A*0201,A*24XX B*07XX, B*3501 C*0401 DRB1*0101 DRB1*1501 DRB5*0101.

Inventive Method: A*0201,A*2402, B*0701, B*3501, C*0401, DRB1*0101, DRB1*1501, DRB5*0101.

Sample #12:

PCR-SSP: A*0201, B*1301, B*44XX, C*0601, DRB1*0403, DRB1*1401, DRB3*0101, DRB4*01XX.

Inventive Method: A*0201, B*1301, B*4402, C*0601, DRB1*0403, DRB1*1401, DRB3*0101, DRB4*0101.

Sample #18:

PCR-SSP: A*0101,A*1101, B*0801, B*1801, C*0701, DRB1*0901, DRB1*14XX, DRB3*03XX, DRB4*01XX.

Inventive method: A*0101, A*1101, B*0801, B*1801, C*0701, DRB1*0901, DRB1*1403, DRB3*0301, DRB4*0101.

The HLA typing from the two methods matched and was found to be in total correlation. With these samples there was 100% specificity, that is, all positive controls or expected positive samples were detected as positive reactions with readings that were at least 3.5 fold that of negative values, and all expected negative controls or samples produce negative results. 100% sensitivity was also observed with the appropriate positive readings for the positive controls or expected positive samples.

The HLA nomenclature at the allelic level is as follows. The first letter denotes the locus, i.e. HLA A and B for Class I, or DRB for Class II. The asterisk (*) denotes DNA typing. The first two numbers designates serological level or equivalent assignments. The third and fourth numbers are the allele level subtypes that are distinguished by DNA typings. The fifth and sixth numbers are usually not displayed because these designate silent mutations, i.e. DNA substitutions that do not produce

changes in protein sequence coding of the final HLA protein antigen. The seventh number, which is usually not displayed as well, denotes a null mutation, which is a mutation that silences the expression of the allele at the protein or mRNA level. There are one to two potential alleles at each locus; however, in homozygous situations where both alleles are identical, only one allele can be identified and typed. Where there is an XX after the first two numbers, it means that only one allele can be identified. This usually means that there may be homozygosity, but in a small number of cases, there may mean that there is a allele that was not detected by the entire panel of primers either because the panel cannot be all inclusive or because the allele is new and previously undiscovered.

In all instances, positive reactions observed on the PCR-SSP agarose gels corresponded to positive OD values that are at least 3.5-fold that of negative controls or negative wells on the plate reader. In this respect, it is instructive to note that because the inventive method of this example is amenable to larger sets of primer pairs, it detects several of the alleles at a higher level of resolution than the PCR-SSP method. Hence, there were several XX assignments for the third and fourth numbers in some of the alleles tested by PCR-SSP. However, the PCR-SSP method is fully capable of typing every sample to the same degree of resolution as the inventive method of this example even though is far more laborious.

EXAMPLE 3 AMPLIFICATION OF HLA SEQUENCES WITH AN IMMOBILIZED ALLELE-SPECIFIC PRIMER.

This method involves the amplification of HLA sequences using allele-specific primers, where one of the pair of amplification primers is immobilized to a solid phase. The other primer constituting a primer pair contains a detectable label and is initially free in solution. Reference DNAs were used as the template nucleic acid. The reference DNAs are from a panel of DNA that was used for the UCLA DNA Exchange Program. Primers directed to detecting class II HLA alleles were used in this example. In this example, the following immobilization primers contained an amine group followed by a C6 linker: SEQ ID NO: 189, DR06, CGTTTCTTGAGCAGGCTAAGTG; SEQ ID NO: 190, DR07, CGTTTCTTGAGTACTCTACGGG; SEQ ID NO: 191, DR08, ACGTTTCTTGAGCAGGTAAAC; SEQ ID NO: 192, DR09, CGTTTCCTGTGGCAGCCTAAGA; SEQ ID NO: 193, DR10,

CGTTTCTTGGAGTACTCTACGTC; and SEQ ID NO: 277, DRCPT1,
 TGGCGTGGGCGAGGCAGGGTAACTTCTTTA. The primers were immobilized to a
 Xenobind™ (Covalent Binding Microwell Plates), Xenopore, Hawthorne, NJ) plate
 according to the manufacturer's instructions. The DNA samples were isolated from
 5 reference samples known HLA allele sequences. The amplification buffer and
 components are the same as in Example 1 for the class II amplification. The buffer
 containing Taq and the proper amplification reagents were added to the microtiter wells.
 The other member of the primer pairs were biotinylated at their 5' ends and were as
 follows: SEQ ID NO:222, DR39, TGCACTGTGAAGCTCTCAC, SEQ ID NO:223,
 10 DR40, CTGCACTGTGAAGCTCTCCA. The primers were paired in separate microtiter
 wells as follows for sample 219 and sample 223:

Mix	Primer 1	Primer 2	Specificity
1	DR09	DR39	DR16
2	DR09	DR40	DR15
3	DR10	DR39	DR 3A,11A,13A,14A
4	DR10	DR40	DR 3B,11B,13B,14B
5	DR08	DR39	DR 4A
6	DR08	DR40	DR 4B
7	DR07	DR39	DR 8
8	DR07	DR40	DR12
9	DR06	DR39	DR53
10	Drcapt1	DR39,40	positive control
11	none	none	none
12	none	none	none

The amplification program was carried out as in Example 1. After
 amplification, the plate was washed twice with 0.1% BSA in PBS at pH 7.4.
 ExtrAvidin® Peroxidase conjugate was diluted 1:2000 in 4% BSA in PBS at pH 7.4.
 50.0 ul was added to each well. The plate is incubated at 37 °C for 30 minutes and then
 30 washed six times with 200 ul of PBS pH 7.4 in each well by the plate washer. 50.0 ul of
 liquid substrate (3,3',5,5' – Tetramethylbenzidine) is added to each well and incubated at
 37 °C for 30 minutes. 50.0 ul of 1N HCl is added to each well to stop the reaction. In
 parallel with the immobilized PCR method just described, PCR-SSP using the above
 listed primers pairs was carried out and the samples were typed by running them on
 35 agarose gels. The results of the PCR-SSP typing method and the immobilized PCR
 primer method carried out in this example were in complete agreement. The expected

typing of the reference DNA and the genotypes determined using PCR-SSP and immobilized PCR of this example were the same:

DNA ID	HLA Genotype of the Reference DNA	Genotype determined by PCR-SSP and the Inventive Method
219	DR1501, DR0404	DR15, DR04B
223	DR1101, DR0403	DR3,11,13,14A, DR04B

Thus, this example shows that PCR can be carried out with an immobilized primer to successfully genotype samples for their HLA allele sequences.

EXAMPLE 4- MULTIPLEXING OF POSITIVE CONTROLS INTO EVERY WELL

A positive control in every well can be used to distinguish from the allele specific reactions by virtue of having a different fluorophore or enzyme-substrate. For example, if the allele specific reaction and the positive control use different fluorophores, then the excitation and emission wavelengths for both fluorophores will be used. The positive control amplified fragment will be longer than the allele specific reaction so that the allele specific reaction would be favored. The positive controls would be captured by the same capture probe as the allele specific if the capture probe is conserved. If the allele specific capture probes are used, then the positive controls may have complementary sequences to the allele specific capture probes at its 5' end of the primer that is labeled.

In this method, positive control primers would be used. For example, SEQ ID NO:270: 5' DPA - E (PC), 5'GATCCCCCTGAGGTGACCGTG and SEQ ID NO:271: 3'DPA - F (PC), 5'CTGGGCCCCGGGGGTCATGGCC are used. SEQ ID NO: 270 would be labeled with the amine linker at the 5' end and is designated 5'PC. SEQ ID NO: 271 is the 3' positive control primer and would be labeled with a fluorophore (e.g., fluorescein at the 5' end) and is designated 3'PC - (CTGGGCCCCGGGGGTCATGGCC). These primers can be added to PCR mixes and used as internal controls in each well by detected their specific fluorescent signal.

EXAMPLE 5- DETECTION OF HLA SEQUENCES USING MOLECULAR BEACON PROBES

Molecular beacon probes could be used to detect allele-specific amplification products. Briefly, amplification of HLA allele sequences using HLA-specific primers is first carried out. Then molecular beacon probes that hybridize with HLA alleles sequences are hybridized to denatured amplification products. If the molecular beacon probe hybridizes then the fluorophore is no longer quenched and fluorescence would be exhibited and detected.

Fluorophore – quencher probes would be constructed from the HLA sequences given in Table 1 and 2. The loop portion of the probe would be constructed so that the sequence matched the polymorphic sequences of the HLA sequences similar to the sequences given in Tables 1 & 2. At the 5' termini there would be 5 nucleotides of T ending with the fluorophore (e.g. 5-(2'-aminoethyl) aminonaphthalene-1-sulfonic acid (EDANS) at the 5' end. At the 3' end there would be a poly-A tail of 5 nucleotides ending with the quencher (e.g. 4-(4'-dimethylaminophenylazo)-benzoic acid (DABCYL) at the 3' end.

Following PCR amplification, the products are denatured by incubating them at 100°C for 10 minutes and then diluted in hybridization buffer. Diluted Class I products are added to the Molecular Beacon tray containing the Class I fluorophore and quencher probes. Similarly, the Class II diluted PCR product is added to the Class II Molecular Beacon tray.

To make up the tray containing the molecular beacon primers, 0.5-1.0 uM concentration of molecular beacon primers are made. The molecular beam primers would be added to wells containing allele-specific amplification products. The Molecular Beacon tray is allowed to incubate at 45-57 °C for a period of time to allow for hybridization.

When the complementary target is encountered the fluorophore is exposed and the probe can fluoresce. The tray is read by a fluorescent reader with the excitation set at 336 nm and the emission set at 490 nm. Positive reactions are identified by strong fluorescent reading and data readings are stored as a spreadsheet file. Positive reactions are identified by values over threshold. Threshold is determined by numerical values that are at least 3 times over the value of the negative control and the average of the negative reaction values.

EXAMPLE 6 IN SITU AMPLIFICATION VARIATION

Oligonucleotide primers will be used that are designed to hybridized to the polymorphic regions of HLA A, B, C loci for Class I and HLA DR and DQ for Class II. The sequences and location of these primers are given in Tables 1 & 2. The primers listed in Tables 5 and 6 are biotinylated. All primers are adjusted to their optimum concentration of 100 ng/ul. Primer pair mixes will be set up to aliquot into PCR trays. Two different 96 well trays will be set up see Tables 3 & 4. The mixes will be aliquoted into labeled 1.2 ml tubes according to the volumes given in Tables 3 & 4. A 96 well tray dotting machine is utilized to dot the PCR Trays. The polypropylene trays are labeled with their tray identification, i.e., Class I tray and dotting number. 200 trays can be dotted with each 1.1 ml Primer Mix set. The 96 well dotting machine is adjusted to a draw volume of 250 ul and a dispense volume of 5.0 ul. Fifty 96 well trays at a time can be dotted. Once the primers are dotted 17.0 ul of mineral oil is added to each well. The PCR tray is then covered with adhesive tape. The trays are then boxed and stored at – 20°C until use.

The sample would be a cell prep containing nucleated cells, or a crude cell prep with inhibitory proteins (heme) removed. First, 50-100 mg of cell prep are diluted in 100-200 ul of dH₂O. Then Proteinase K (20 mg/ml) (Fisher Scientific) would be added (100 ul is used for every 50 mg of cell prep) and the sample is incubated to digest proteins in the sample. The lysate sample is incubated at 100 °C for 1 minute to inactivate the Proteinase K.

PCR amplification would be accomplished by adding the DNA mixture to the PCR tray and placing the tray in a thermal cycling oven. For DNA mixture aliquot - lysate sample, 4.0 ul Taq polymerase (5U/ul), and 600.0 ul PCR Mix into a labeled 1.5ml tube and place on ice. The PCR buffers are the sample as in Example 1: For Class I trays, PCR Mix – 30 mM Ammonium Chloride, 150 mM TRIS-HCl pH 8.8, 4 mM MgCl₂, and 166 uM dNTP; For Class II trays, PCR Mix – 100 mM KCl, 20 mM TRIS HCl pH 8.8, 0.2% Triton X-100, 3.4 mM MgCl₂, and 166 uM dNTP.

A Liquid Sample Dispensing machine would be used to add the DNA mixture to tray PCR tray. The 250 ul dispensing syringe would be employed. The machine would be set to add 5.0 ul to a 96 well microtiter tray. The appropriate PCR tray would be placed in the machine. The DNA mixture would be vortexed and then 5.0 ul of DNA mixture would be dispensed into each of the 96 wells of the PCR tray. The tray would then be placed in the thermal cycling oven.

After PCR amplification, diluted capture oligonucleotide would be added to the wells. 5.0 ul of capture oligonucleotide at a concentration of 50 ng/ul would be added to each well. The tray would be placed in the thermal cycling oven and a capture thermal cycle program run. After the capture thermal cycling, the PCR products are now hybridized with the capture oligonucleotide. The hybridized PCR products are diluted. A dilution of 1:10 with PBS at pH 7.4 is optimum. 90.0 ul of PBS at pH 7.4 is added to each well in the PCR tray. 15.0 ul of the diluted PCR product is transferred by the 96 well dotting machine into a new covalent binding plate containing 50.0 ul of PBS at pH 7.4 in each well. The plate would be incubated overnight at room temperature so that the hybridized PCR product with the capture oligonucleotide with its amine linker at the 5' end can bind to the plate. The unbound products are removed by washing. Using the plate washer, the plate is washed twice with 0.1% Tween 20 in PBS at pH 7.4. Avidin peroxidase conjugate is diluted 1:2000 in 4% BSA in PBS at pH 7.4. 50.0 ul is added to each well. The plate is incubated at 37 °C for 30 minutes.

The plate is washed six times with 200 ul of PBS pH 7.4 in each well by the plate washer. 50.0 ul of liquid substrate (3,3',5,5' – Tetramethylbenzidine) is added to each well and incubated at 37 °C for 30 minutes. 50.0 ul of 1N HCl is added to each well to stop the reaction. Trays are read on a microtiter plate reader by setting the filter to 450 nm. The data readings would be stored as a spreadsheet file and analyzed. Positive reactions are identified by values over threshold. Threshold is determined by numerical values that are at least 3.5 times over the value of the negative control and the average of the negative reaction values.

EXAMPLE 7- IN SITU AMPLIFICATION- MOLECULAR BEACON VARIATION

HLA-specific Molecular beacon probes would be constructed as in Example 5. A tray of molecular beacon probes would be spotted into microtiter plates. The template nucleic acid is contained in a cell prep containing nucleated cells or a crude cell prep with inhibitory proteins (heme) removed. First, 50-100 mg of cell prep are diluted in 100-200 ul of dH₂O. Then Proteinase K (20mg/ml) (Fisher Scientific) would be added (100 ul is used for every 50 mg of cell prep) and the sample is incubated to digest proteins in the sample. The lysate sample is incubated at 100°C for 1 minute to inactivate the Proteinase K.

PCR amplification would be accomplished by adding the DNA mixture to the PCR tray and placing the tray in a thermal cycling oven. HLA locus-specific primers

are utilized to amplify HLA Class I and Class II products. For Class I primers are selected to amplify Class I exon 2 and exon 3 products. For Class II, primers are selected to amplify Class II exon 2 products. For DNA mixture aliquot - lysate sample, 4.0 ul Taq polymerase (5 U/ul), and 600.0 ul PCR Mix into a labeled 1.5 ml tube and place on ice.

- 5 The PCR buffers are the sample as in Example 1. Following PCR amplification, the PCR product is denatured by incubation at 100 °C for 10 minutes and then diluted in hybridization buffer.

Diluted Class I products would be added to the Molecular Beacon tray containing the Class I fluorophore and quencher probes. Similarly, the Class II diluted PCR product would be added to the Class II Molecular Beacon tray. The Molecular Beacon tray is allowed to incubate at 45-57 °C for a period of time to allow for hybridization. When the complementary target is encountered the fluorophore is exposed and the probe can fluoresce. The tray is read by a fluorescent reader with the excitation set at 336 nm and the emission set at 490 nm. Positive reactions are identified by strong fluorescent reading and data readings are stored as a spreadsheet file. Positive reactions are identified by values over threshold. Threshold is determined by numerical values that are at least 3.5 times over the value of the negative control and the average of the negative reaction values.

20 EXAMPLE 8-TISSUE BLOCK SECTION VARIATION

The tissue block section method is a variation of the molecular beacon method with the use of a paraffin embedded tissue sample. The construction of the fluorophore-quencher probe is carried out as in Example 8 (Construction of the fluorophore-quencher probe). Molecular beacon tray set up would be carried out as in Example 8.

25 The amplification of sequences on a paraffin block sample would occur on a glass slide which will necessitate dotting the PCR mixes on a glass slide. Samples embedded in paraffin are sectioned and each slide would be added to a glass slide. The specific primer mix and DNA mixture would be added to an individual glass slide. HLA locus primers are utilized to amplify HLA Class I and Class II products. For Class I primers are selected to amplify Class I exon 2 and exon 3 products. For Class II, primers are selected to amplify Class II exon 2 products. There will be 96 individual slide made to complete the Class I or Class II sets. After adding the mix, the glass slide would be sealed with a cover slip. The slides are placed in the thermal cycling oven and the PCR

program for slides would be run. 1 cycle of 96 °C for 30 seconds followed by 34 cycles of 96 °C for 30 seconds, 61 °C for 60 seconds, 72 °C for 60 seconds.

Following PCR amplification, the PCR product would be denatured by incubation at 100 °C for 10 minutes and then diluted in hybridization buffer (0.9 M NaCl, 90 mM sodium citrate, 1 mM EDTA, 0.1% Ficoll, 0.3% BSA, and 0.5% SDS).

Diluted Class I products are added to the Molecular Beacon tray containing the Class I fluorophore and quencher probes. Similarly, the Class II diluted PCR product would be added to the Class II Molecular Beacon tray. The Molecular Beacon tray would be allowed to incubate at 45-57 °C for 1 hour to allow for hybridization.

When the complementary target is encountered the fluorophore is exposed and the probe can fluoresce. The tray would be read by a fluorescent reader with the excitation set at 336 nm and the emission set at 490 nm. Positive reactions are identified by a strong fluorescent reading; positive reactions are identified by values over threshold. Threshold is determined by numerical values that are at least 3 times over the value of the negative control and the average of the negative reaction values.

The data readings are then stored as a spreadsheet file. In this manner, HLA genotyping could be achieved.

All publications, patents and patent applications mentioned in this specification are herein incorporated by reference into the specification in their entirety for all purposes. Although the invention has been described with reference to preferred embodiments and examples thereof, the scope of the present invention is not limited only to those described embodiments. As will be apparent to persons skilled in the art, modifications and adaptations to the above-described invention can be made without departing from the spirit and scope of the invention, which is defined and circumscribed by the appended claims.

Sequence

Table 1

Primer		SEQUENCE (5' - 3')												MER																		
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	
C101	5'	HLA-C ex2 221-239	C	C	G	A	G	T	G	A	A	C	C	T	G	C	G	G	A	A	A											19
C102	5'	HLA-C Ex2 249-268	T	A	C	T	A	C	A	A	C	C	A	G	A	G	C	G	A	G	G	A										20
C103	5'	HLA B&C Ex2 210-228	C	A	C	A	G	A	C	T	G	A	C	C	G	A	G	T	G	A	G											19
C104	5'	HLA-C Ex2 123-140	A	G	T	C	C	A	A	G	A	G	G	A	G	C	A	G	C	C	G											18
C105	5'	HLA-A&C Ex2 5-25	C	C	A	C	T	C	C	A	T	G	A	G	G	T	A	T	T	T	C	T										20
C106	3'	HLA-C Ex3 243-263	T	C	T	T	C	T	C	C	A	G	A	A	G	C	A	C	C	A	T											19
C107	3'	HLA-C Ex3 243-263	C	A	G	G	T	C	A	G	T	G	A	T	C	A	T	C	C	A												19
C108	3'	HLA-B&C Ex3 195-213	C	C	T	C	C	A	G	G	T	A	G	G	C	T	C	T	C	C	A											18
C109	3'	HLA-C Ex4 234-251	C	A	G	C	C	C	C	T	C	G	C	T	G	C	T	G	C	A	T											18
C110	3'	HLA-C Ex3 258-275	C	G	C	G	C	G	C	T	G	C	A	G	C	G	T	C	T	C	A	G										19
C111	3'	HLA-C Ex3 195-213	C	C	T	C	C	A	G	G	T	A	G	G	C	T	C	T	C	T												18
C112	3'	HLA-C Ex4 31-49	C	T	C	A	G	G	G	T	G	A	G	G	G	C	T	C	T	C	A											18
C113	3'	HLA-C Ex3 134-151	T	G	A	G	C	C	A	G	C	C	A	T	G	T	C	C	A	T	C	C	A									19
C114	3'	HLA-B & C Ex3 18-36	G	G	T	C	G	C	A	G	C	C	A	T	A	C	C	A	G	T	C											18
C115	5'	HLA-B & C Ex3 59-76	C	C	G	C	G	G	G	T	A	T	G	A	C	C	A	G	T	C												19
C116	3'	HLA-C Ex4 4-23	G	C	G	T	C	T	C	T	C	T	C	C	T	C	C	A	T	C	T	T										20
C117	3'	HLA-C Ex4 4-23	A	G	C	G	T	C	T	C	C	T	T	C	T	C	C	A	T	C	T	T										19
C118	5'	HLA-C Ex3 134-151	T	C	C	G	C	G	G	T	A	T	G	A	C	C	A	G	T	A												18
C119	3'	HLA-C Ex3 25-42	G	C	C	C	C	A	G	G	T	C	G	C	A	G	C	C	A	C	A											18
C120	5'	HLA-C Ex2 195-213	A	C	A	A	G	C	G	C	C	A	G	G	C	A	C	A	C	T	C											19
C121	3'	HLA-ABC Ex3 216-233	G	A	G	C	C	A	C	T	C	C	A	C	G	C	A	C	T	C	T											20
C122	3'	HLA-A & C Ex3 456-214	C	C	C	T	C	C	A	G	G	T	A	G	G	C	T	G	T	C	A	T	G									17
C123	3'	HLA-B & C Ex3 65-84	T	C	G	T	A	G	G	C	T	A	A	C	T	G	G	C	A													19
C124	3'	HLA-C Ex3 131-148	C	C	G	C	C	G	T	G	T	C	C	G	C	G	C	A														18
C125	5'	HLA-C Ex2 252-270	T	A	C	A	A	C	C	A	G	A	G	C	A	G	A	G	C	C	G	A										19
C126	5'	HLA-C Ex2 253-270	A	C	A	A	C	C	A	G	A	G	C	A	G	T	T	C	G	T	G	C	A									19
C127	5'	HLA-C Ex2 85-103	A	C	G	A	C	A	C	A	C	G	C	A	G	T	C	G	C													17
C128	5'	HLA-C Ex2 229-246	G	C	G	C	A	G	G	T	T	C	C	G	C	A	G	G	C													18
C129	3'	HLA-A Ex3 216-233	G	A	G	C	C	A	C	T	C	C	A	C	G	C	A	C	C	G												18
C130	3'	HLA-ABC Ex3 216-233	G	A	G	C	C	A	C	T	C	C	A	C	G	C	A	C	T	C	T											19
C131	3'	HLA-A Ex3 195-213	C	C	T	C	C	A	G	G	T	A	G	G	C	T	C	C	T	C	T	G										17
C132	3'	HLA-A Ex3 48-64	C	C	G	C	G	A	G	G	A	A	G	C	C	G	C	C	A													21
C133	5'	HLA-A Ex2 5-25	C	C	A	C	T	C	C	A	T	G	A	G	G	T	A	T	T	C	T	C	T									19
C134	5'	HLA-A Ex2 168-186	C	C	G	G	A	G	T	A	T	T	G	G	G	A	C	C	T	G	C											

Sequence: B6A166

Primer	SEQUENCE (5'-3')	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	525	526	527	528	529	530	531	532	533	534	535	536	537	538	539	540	541	542	543	544	545	546	547	548	549	550	551	552	553	554	555	556	557	558	559	560	561	562	563	564	565	566	567	568	569	570	571	572	573	574	575	576	577	578	579	580	581	582	583	584	585	586	587	588	589	590	591	592	593	594	595	596	597	598	599	600	601	602	603	604	605	606	607	608	609	610	611	612	613	614	615	616	617	618	619	620	621	622	623	624	625	626	627	628	629	630	631	632	633	634	635	636	637	638	639	640	641	642	643	644	645	646	647	648	649	650	651	652	653	654	655	656	657	658	659	660	661	662	663	664	665	666	667	668	669	670	671	672	673	674	675	676	677	678	679	680	681	682	683	684	685	686	687	688	689	690	691	692	693	694	695	696	697	698	699	700	701	702	703	704	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800	801	802	803	804	805	806	807	808	809	810	811	812	813	814	815	816	817	818	819	820	821	822	823	824	825	826	827	828	829	830	831	832	833	834	835	836	837	838	839	840	841	842	843	844	845	846	847	848	849	850	851	852	853	854	855	856	857	858	859	860	861	862	863	864	865	866	867	868	869	870	871	872	873	874	875	876	877	878	879	880	881	882	883	884	885	886	887	888	889	890	891	892	893	894	895	896	897	898	899	900	901	902	903	904	905	906	907	908	909	910	911	912	913	914	915	916	917	918	919	920	921	922	923	924	925	926	927	928	929	930	931	932	933	934	935	936	937	938	939	940	941	942	943	944	945	946	947	948	949	950	951	952	953	954	955	956	957	958	959	960	961	962	963	964	965	966	967	968	969	970	971	972	973	974	975	976	977	978	979	980	981	982	983	984	985	986	987	988	989	990	991	992	993	994	995	996	997	998	999	1000	1001	1002	1003	1004	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017	1018	1019	1020	1021	1022	1023	1024	1025	1026	1027	1028	1029	1030	1031	1032	1033	1034	1035	1036	1037	1038	1039	1040	1041	1042	1043	1044	1045	1046	1047	1048	1049	1050	1051	1052	1053	1054	1055	1056	1057	1058	1059	1060	1061	1062	1063	1064	1065	1066	1067	1068	1069	1070	1071	1072	1073	1074	1075	1076	1077	1078	1079	1080	1081	1082	1083	1084	1085	1086	1087	1088	1089	1090	1091	1092	1093	1094	1095	1096	1097	1098	1099	1100	1101	1102	1103	1104	1105	1106	1107	1108	1109	1110	1111	1112	1113	1114	1115	1116	1117	1118	1119	1120	1121	1122	1123	1124	1125	1126	1127	1128	1129	1130	1131	1132	1133	1134	1135	1136	1137	1138	1139	1140	1141	1142	1143	1144	1145	1146	1147	1148	1149	1150	1151	1152	1153	1154	1155	1156	1157	1158	1159	1160	1161	1162	1163	1164	1165	1166	1167	1168	1169	1170	1171	1172	1173	1174	1175	1176	1177	1178	1179	1180	1181	1182	1183	1184	1185	1186	1187	1188	1189	1190	1191	1192	1193	1194	1195	1196	1197	1198	1199	1200	1201	1202	1203	1204	1205	1206	1207	1208	1209	1210	1211	1212	1213	1214	1215	1216	1217	1218	1219	1220	1221	1222	1223	1224	1225	1226	1227	1228	1229	1230	1231	1232	1233	1234	1235	1236	1237	1238	1239	1240	1241	1242	1243	1244	1245	1246	1247	1248	1249	1250	1251	1252	1253	1254	1255	1256	1257	1258	1259	1260	1261	1262	1263	1264	1265	1266	1267	1268	1269	1270	1271	1272	1273	1274	1275	1276	1277	1278	1279	1280	1281	1282	1283	1284	1285	1286	1287	1288	1289	1290	1291	1292	1293	1294	1295	1296	1297	1298	1299	1300	1301	1302	1303	1304	1305	1306	1307	1308	1309	1310	1311	1312	1313	1314	1315	1316	1317	1318	1319	1320	1321	1322	1323	1324	1325	1326	1327	1328	1329	1330	1331	1332	1333	1334	1335	1336	1337	1338	1339	1340	1341	1342	1343	1344	1345	1346	1347	1348	1349	1350	1351	1352	1353	1354	1355	1356	1357	1358	1359	1360	1361	1362	1363	1364	1365	1366	1367	1368	1369	1370	1371	1372	1373	1374	1375	1376	1377	1378	1379	1380	1381	1382	1383	1384	1385	1386	1387	1388	1389	1390	1391	1392	1393	1394	1395	1396	1397	1398	1399	1400	1401	1402	1403	1404	1405	1406	1407	1408	1409	1410	1411	1412	1413	1414	1415	1416	1417	1418	1419	1420	1421	1422	1423	1424	1425	1426	1427	1428	1429	1430	1431	1432	1433	1434	1435	1436	1437	1438	1439	1440	1441	1442	1443	1444	1445	1446	1447	1448	1449	1450	1451	1452	1453	1454	1455	1456	1457	1458	1459	1460	1461	1462	1463	1464	1465	1466	1467	1468	1469	1470	1471	1472	1473	1474	1475	1476	1477	1478	1479	1480	1481	1482	1483	1484	1485	1486	1487	1
--------	------------------	---	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	---

[illegible]

Primer	SEQUENCE (5'-3')	MER																				
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
C1113	HLA-A Ex3 110-128	C	C	A	A	G	A	G	C	G	C	A	G	G	T	C	C	T	C	T		
C1114	HLA-B Ex2 189-209	A	C	A	C	A	G	A	T	C	A	C	A	A	G	A	C	C	A	A	C	
C1115	HLA-C Ex2 179-197	G	G	A	C	C	G	G	G	A	G	A	C	A	C	A	G	A	A	C		
C1116	HLA-C Ex3 25-41	C	C	C	C	A	G	G	T	C	G	C	A	G	C	C	A	C				
C1117	HLA-C Ex3 183-200	T	C	T	C	A	G	C	T	G	C	T	C	C	G	C	C	G	T			
C1118	HLA-C Ex3 169-186	C	T	C	A	C	G	G	G	C	C	G	C	C	T	C	C	A				
C1119	HLA-C Ex2 221-239	C	C	G	A	G	T	G	A	A	C	C	A	G	C	G	A	A	A			
C1120	HLA-C Ex2 249-268	T	A	C	T	A	C	A	A	C	C	A	G	A	G	C	G	A	G	A		
C1121	HLA-B & C Ex2 210-228	C	A	C	A	G	A	C	T	G	A	C	C	G	A	G	T	G	A	G		
C1122	HLA-C Ex2 123-140	A	G	T	C	C	A	A	G	A	A	G	G	G	G	A	G	C	C	G		
C1123	HLA-A & C Ex2 5-25	C	C	A	C	T	C	C	A	T	C	A	G	G	T	A	T	T	C	C		
C1124	HLA-B & C Ex3 195-213	C	C	T	C	C	A	G	G	T	A	G	G	C	T	A	T	T	C	A		
C1125	HLA-C Ex4 234-251	C	A	G	C	C	C	C	C	C	C	T	C	G	T	G	C	T	C	A		
C1126	HLA-C Ex3 258-275	C	G	C	G	C	G	C	T	G	C	A	G	C	G	T	C	T	T			
C1127	HLA-C Ex3 195-213	C	C	T	C	C	A	G	G	C	A	G	G	C	T	C	C	A	G			
C1128	HLA-C Ex3 18-36	A	G	T	C	G	C	A	G	C	A	G	C	A	A	A	C	A	T	C		
C1129	HLA-C Ex3 246-265	A	G	C	G	T	C	T	C	C	T	T	C	C	C	A	T	T	C	T		
C1130	HLA-B Ex2 219-236	T	A	C	C	G	A	G	A	G	A	A	C	C	T	G	C	G	C	A		
C1131	HLA-B & C Ex3 76-93	C	C	T	T	G	C	C	G	T	C	G	T	A	G	G	C	G	A			
C1132	HLA-B Ex3 69-86	G	T	C	G	T	A	G	G	C	C	G	T	C	C	T	G	G	T	C		
C1133	HLA-A Ex3 20-39	C	C	A	C	G	T	C	G	C	A	G	C	C	A	T	A	C	A	T		
C1134	HLA-B & C Ex2 117-133MM	G	C	C	G	C	G	A	G	T	T	C	G	A	G	A	G	G				
C1135	HLA-B Ex2 220-238	A	C	C	G	A	G	A	G	A	A	C	C	T	G	C	G	A	T			
C1136	HLA-A Ex2 186-205	G	C	C	T	T	C	A	C	A	T	T	C	C	G	T	G	T	T			
C1137	HLA-A Ex3 216-232	A	G	C	C	G	G	T	C	C	A	C	G	A	C	C	G					
C1138	HLA-A Ex2 5-25	C	G	A	C	T	C	C	A	T	G	A	G	G	T	A	T	T	C	A	C	
C1139	HLA-B Ex2 230-246	C	C	T	G	C	G	C	A	C	C	G	C	T	C	C						
C1140	HLA-A & B 224-262	C	T	C	T	G	G	T	T	G	T	A	G	T	A	G	C	G	A			
C1141	HLA-A Ex3 63-80	G	G	G	T	A	C	C	G	G	C	A	G	G	A	C	G	C	T			

Sequence TCGA1430

Primer		SEQUENCE (5' - 3')																														MER																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																								
		C	A	T	G	A	G	G	T	A	T	T	T	C	T	A	C	A	C	C	G	C	T																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																	

Table 2

53

Sequence

DR17	3'	DR2R37F-2R	T	C	G	C	T	G	T	C	G	A	A	G	C	G	C	A	C	G	A		19	T
DR18	3'	DR2R37L-1R																				18	C	
DR19	3'	DR2R37N-2R	C	G	C	T	G	T	C	G	A	A	A	G	C	G	C	A	C	G	T	19	A	
DR20	3'	DR2R37S-1R																				17	C	
DR21	3'	DR2R37Y-1R	G	C	T	G	T	C	G	A	A	A	A	G	C	G	C	A	C	G	T	18	T	
DR22	5'	DR2S37YA-1	C	G	C	T	G	T	A	G	C	G	C	G	A							16	T	
DR23	3'	DR2R47F-2R	T	C	C	G	T	C	A	C	G	C	C	G	A	G						18	G	
DR24	5'	DR2S52B-3	G	A	G	T	A	C	C	G	C	G	G	T	G	A	G	C	A	T		19	A	
DR25	3'	DR2R57D-1R	C	T	G	T	T	C	C	A	G	T	A	C	T	C	G	C	G	C	T	19	A	
DR26	3'	DR2R57S-1R	T	G	T	T	C	C	A	G	T	A	C	T	C	G	C	G	A			21	T	
DR27	3'	DR2R57V-1R	C	T	G	T	T	C	C	A	G	G	A	C	T	C	G	C	T	C	T	21	A	
DR28	3'	DR2R58E-1R	T	C	A	G	C	T	G	T	C	C	A	G	T	A	C	T	C			19	T	
DR29	3'	DR2R67F-2R	C	G	C	C	T	G	T	C	T	T	C	C	A	G	G	A	T			19	A	
DR30	3'	DR2R67I-2R	C	C	C	G	C	T	C	G	T	T	C	C	A	C	C	A				21	A	
DR31	3'	DR2R70QR-3	C	A	C	C	G	C	G	C	C	C	C	T	C	T	G					18	C	
DR32	3'	DR2R71A-2R																				15	G	
DR33	3'	DR2R74E-1R	T	G	C	A	A	T	A	G	G	T	G	T	C	C	A	C	C	T	C	19	G	
DR34	3'	DR2R74L-1R	T	G	C	A	G	T	A	G	T	A	A	T	T	G	T	C	C	A	G	24	C	
DR35	3'	DR2R74Q-2R	G	T	G	T	C	T	G	C	A	G	T	A	T	T	G	T	C	C	C	23	G	
DR36	3'	DR2R74R-1R	G	T	G	T	C	T	G	C	A	G	T	A	T	T	G	T	C	C	C	17	G	
DR37	3'	DR2R76G-1R																				23	T	
DR38	3'	DR2R81Y-1R	C	T	C	T	C	C	A	C	A	A	C	C	G	T	A	G	T	G	T	19	G	
DR39	3'	DR2R86G-1R	T	G	C	A	C	T	G	A	A	G	C	T	C	T	C	A	C			20	T	
DR40	3'	DR2R86V-1R	C	T	G	C	A	C	T	G	A	A	G	C	T	C	T	C	A			20	T	
DR41	3'	DR2R78A-1R	C	C	C	C	G	T	A	G	T	G	T	A	G	T	C	C	A	C	C	18	G	
DR42	3'	DR2R74C-1R																				18	G	
DR43	3'	DR2R74T-1R																				19	C	
DR44	3'	DR2R60T-1R	C	C	T	T	C	T	G	C	T	G	T	T	C	C	A	G	T	C	C	19	C	
DR45	3'	DR2R60G-1R	T	C	C	T	T	C	T	G	C	T	G	T	T	C	C	A	G			19	C	
DR46	3'	DR2R85A-1R	C	T	C	C	G	T	C	A	C	C	G	C	C	G	A	C	A	C	A	17	T	
DR47	3'	DR2R47F	C	T	C	C	G	T	C	A	C	C	G	C	C	G	T	A				18	T	
DR48	3'	DR2R47Z-1R	C	T	C	C	G	T	C	A	C	C	G	C	C	G	T	A				21	C	
DR49	3'	DR2R30a	C	T	C	C	T	C	C	T	G	T	A	T	G	G	A	A	G	T	G	21	G	
DR50	3'	DR2R30b	C	T	C	C	T	C	C	T	G	T	A	T	G	G	A	A	G	T	A	20	T	
DR51	3'	DR2R37a	T	C	C	G	C	T	G	T	C	G	A	A	G	C	C	A	C	G	T	19	T	
DR52	3'	DR2R37b	C	G	C	T	G	T	C	G	A	A	G	C	C	A	C	G	G	A		19	G	
DR53	3'	DR2R37c	C	G	C	T	G	T	C	G	A	A	G	C	C	A	C	G	T	C		19	T	
DR54	3'	DR2R37d	T	C	G	C	T	G	T	C	G	A	A	G	C	C	A	C	G	A		19	T	
DR55	3'	DR2R37e	T	C	G	C	T	G	T	C	G	A	A	G	C	C	A	C	G	A		19	T	
DR56	3'	DR2R38a	A	C	G	T	C	G	T	C	G	A	A	G	C	G	C	A	C	G		20	C	

Table 3

	5' Primer	3' Primer	Specificity	Size (bp)
A01	1 C1099	C1137	A*0101, 0102	629
A02	4 C1099	C1030	A*3601	630
A03	2 C1108	C1113	A*0201-17	489
A04	3 C1103	C1110	A*0301,0302	628
A05	15 C1102	C1029	A*1101,1102,6601	552
A06	6 C1104	C1085	A*2301	557
A07	5 C1097	C1113	A*2301,A*2401-07	464
A08	7 C1104	C1031	A*2402-05, 2407	557
A09	10 C1106	C1109	A*2501	400
A10	8 C1077	C1029,021	A*2501,2601,2603,2605,6601,6602,4301	170
A11	9 C1041	C1109	A*2501,2601-05,6601,6602,3401,3402	440
A12	11 C1101	C1109	A*2601,2602,2604,4301	400
B01	12 C1034	C1109	A*4301	442
B02	13 C1077,141	C1030	A*3401,3402	170
B03	14 C1102,142	C1109	A*3401,3402,6601,6602	419
B04	16 C1034	C1111	A*2901,2902	465
B05	17 C1107	C1112	A*3001-05	561
B06	18 C1138	C1143	A*3101	198
B07	19 C1033	C1072	A*3201	259
B08	21 C1033	C1111	A*3201,7401	628
B09	20 C1138	C1136	A*3301-03	200
B10	22 C1102	C1113	A*6801,6802,6901	447
B11	23 C1102	C1032	A*6901	383
B12	24 C1120	C1100	A*8001	494
C01	25 C1120	C1133	A*01,*11,*3601,*3401,*8001	300
C02	79 C1051	C1059	B*5101-05,51v,51GAC,5201	401
C03	80 C1041	C1059	B*5101-05,51v,51GAC,7801-02,1509	451
C04	81 C1040	C1059	B*5201	440

Table 162n260

		5' Primer	3' Primer	Specificity	Size (bp)
C05	77	C1043	C1056,091	B*3501-09,3511,5301	389/340
C06	28	C1041	C1064	B*0702-05,8101	619
C07	29	C1114	C1064	B*0703	600
C08	30	C1043	C1055	B*0801,0802,B51GAC,B*4406	543
C09	31	C1043	C1063	B*0801,0802	606
C10	36	C1046,089	C1132,098	B*4402-06	546/481
C11	34	C1083	C1058	B*4501,45v,4901,5001	600
C12	35	C1050	C1062	B*4501,45V,1514	536
D01	42	C1081	C1058	B*1301-03	486
D02	43	C1045	C1014	B*1401,1402	389
D03	44	C1048	C1071	B*1402,3904	187
D04	67	C1081	C1086	B*1501,1502,1504-08,1511,1512,1514,1515,1519-21,1525,1526N,1528	124
D05	68	C1040	C1057	B*1501,1503-07,1512,1514,1519,1520,1524,1525,4802,4003,13x15,1526N	421
D06	70	C1052	C1057	B*1503,1518,1523,1529,4802,3907,72v,Cw0703	486
D07	72	C1039	C1076	B*1509,1510,1518,1521,1523	562
D08	73	C1081	C1062,082	B*1512,1514,1519	636/637
D09	74	C1041	C1124	B*1508,1511,1515,1522,A*68,2501,2601-05,3401,6601-02	553
D10	65	C1042	C1067	B*1516,1517	516
D11	47	C1051,139	C1060	B*3801,3802	498/508
D12	48	C1052	C1060	B*3801,3802,3901-08,6701	612
E01	45	C1050	C1060	B*3901-08,6701	507
E02	46	C1049	C1060	B*6701	548
E03	51	C1042	C1066	B*5701-03	351
E04	52	C1081	C1140	B*5701-03,1513,1516,1517,1524,1301-03,13x15	143

OBJECT PAGE

	5' Primer	3' Primer	Specificity	Size (bp)
E05	50 C1042	C1056	B*5801-03	374
E06	49 C1051	C1065	B*5801,5104,5301,1513	319
E07	53 C1037	C1057	B*1801,1802	458
E08	41 C1094	C1070	B*4001,4007	607
E09	40 C1089	C1061	B*4001-04,4006-08,4701	627
E10	38 C1089	C1090	B*4002-06,4008,4101,4102,4501,45v,4901,5001,4402-05,4701	566
E11	33 C1051	C1058	B*4901,5901	385
E12	32 C1094	C1067	B*4901,5001,4005,2704,2706,45v	635
F01	57 C1134	C1074	B*5401	421
F02	55 C1080	C1058	B*5401,5501,5502,5601,4501,45v,5001	383
F03	54 C1052	C1074	B*5501,5502,5601,5602,7301,3906	422
F04	56 C1047	C1076	B*5601,5602	551
F05	58 C1094	C1095,096	B*2701-09	149/150
F06	75 C1041	C1065	B*3501-04,3506-09,3511,5301,1502,1513,5104,1521,4406	369
F07	76 C1038	C1075	B*3501-13,18,7801-02,1522	128
F08	59 C1038	C1055	B*3701,B*4406,B51GAC	606
F09	60 C1040	C1131	B*3701,3902,3908	422
F10	37 C1040	C1063	B*4101,4102	605
F11	63 C1047	C1063	B*4201,42v	594
F12	66 C1078	C1079	B*4601	459
G01	61 C1040	C1069	B*4701	414

Table 1

		5' Primer	3' Primer	Specificity	Size (bp)
G02	64	C1052	C1070	B*4801,8101	567
G03	39	C1040	C1084	B*4801,4001-06, weak B41	465
G04	69	C1088	C1065	B*4802	487
G05	71	C1088	C1076	B*4802,1503,1509,1510,1518,1523,1529,72v	691
G06	62	C1120	C1074	B*7301	289
G07	78	C1050	C1059	B*7801-02,1509	400
G08	26	C1051,087,092,139	C1073	Bw4	1330
G09	27	C1080	C1073	Bw6 not B73	1340
G10	82	C1121	C1116	Cw*0101,0102	341
G11	83	C1119	C1021	Cw*0201,0202,1701	522
G12	84	C1121	C1129	Cw*0302,0303,0304	565
H01	85	C1119	C1019	Cw*0401,0402	331
H02	86	C1119	C1126	Cw*0501	564
H03	87	C1120	C1014	Cw*0602	297
H04	88	C1015	C1125	Cw*0701,0702,0703	1062
H05	89	C1115	C1036	Cw*0701	516
H06	90	C1120	C1035	Cw*0702,0703	302
H07	91	C1120	C1076	Cw*0703,A*2604	494
H08	92	C1120	C1126	Cw*0704	536
H09	93	C1027	C1028,117	Cw*0802 Cw*0801/3	161/625
H10	94	C1025	C1129	Cw*0303	523

Table 1

	5' Primer	3' Primer	Specificity	Size (bp)
H11	95 C1026	C1129	Cw*0302,0304	522
H12	96 Neg. Control			0

Table 4

Tray	Mix	Primer S	Primer AS	label
A01	DRM01	DR13	DR31	DR2R70QR DRB1*0102
A02	DRM02	DR13	DR20	DR2R37S DRB1*0101,0102,0103,0104
A03	DRM03	DR13	DR30	DR2R67I DRB1*0103
A04	DRM04	DR13	DR39	DR2R86G DRB1*0101,0103
A05	DRM05	DR13	DR40	DR2R86V DRB1*0102,0104
A06	DRM06	DR02	DR39	DR2R86G DRB1*1001
A07	DRM07	DR02	DR25	DR2R57D DRB1*1001
A08	DRM08	DR09	DR15	DR2R30H DRB1*1503
A09	DRM09	DR09	DR17	DR2R37F DRB1*1608
A10	DRM10	DR09	DR23	DR2R47F DRB1*1501,1502,1503,1504,1505,1506,1508,1510
A11	DRM11	DR09	DR48	DR2R47? DRB1*1507,16XX
A12	DRM12	DR09	DR25	DR2R57D DRB1*1502
B01	DRM13	DR09	DR30	DR2R67I DRB1*1510,1605,1607
B02	DRM14	DR09	DR29	DR2R67F DRB1*1601,1603?,1604
B03	DRM15	DR09	DR32	DR2R71A DRB1*15XX
B04	DRM16	DR09	DR34	DR2R74L DRB1*1604
B05	DRM17	DR09	DR39	DR2R86G DRB1*1502,16XX
B06	DRM18	DR09	DR40	DR2R86V DRB1*1501,1503,1504,1505,1506,1507,1509,1510
B07	DRM19	DR10	DR12	DR17-1R DRB1*0301,0304,5,6,8-16

Table 4-46

Tray	Mix	Primer S	Primer AS	label	
B08	DRM20	DR10	DR21	DR2R37Y	DRB1*11XX,1303,07,11-14,17,21-25,30,33,37,38,44,45,1425
B09	DRM21	DR10	DR19	DR2R37N	DRB1*0301,02,05-15,1109,16,20,28,1301,02,05,06,09,10,15,16,18,20,26-29,31,32,34-36,39-43,1402,03,06,09,12,13,17-19,21,24,27,29,30,33
B10	DRM22	DR10	DR17	DR2R37F	DRB1*1110,12,13,17,1308,19,1401,04,05,07,08,10,11,14-16,20,22,23,26,28,31,32,34-36
B11	DRM23	DR10	DR23	DR2R47F	DRB1*0301,04,05,07-14,1101-16,18-36,38,39,1301,02,04,06,14-18,20-25,27-31,34,35,39,41-45,1417,21,30,33,35,
B12	DRM24	DR10	DR48	DR2R47?	DRB1*0302,03,06,1117,37,1303,07,08,12,13,19,26,32,33,36-38,40,1401-16,18-20,22-29,31,32,34,36
C01	DRM25	DR10	DR25	DR2R57D	DRB1*0301-07,11,13-16,1301,02,05-11,14-20,22-25,27-29,34-37,39-42,44,1402,03,06,09,12,14,15,17-21,23,24,27,29,30,33,36
C02	DRM26	DR10	DR26	DR2R57S	DRB1*0312,1303,04,12,13,21,30,32,33,38,1413,
C03	DRM27	DR10	DR27	DR2R57V	DRB1*1331
C04	DRM28	DR10	DR28	DR2R58E	DRB1*11XX,1411,
C05	DRM29	DR10	DR29	DR2R67F	DRB1*1101,03-06,09-12,15,22-25,27-30,32,33,35,37-39,1305,07,11,14,18,21,24,26,42,1415,22,25,27
C06	DRM30	DR10	DR30	DR2R67I	DRB1*1102,14,16,20,21,1301-04,08,10,15,16,1922,23,27,28,31-41,45,1416
C07	DRM31	DR10	DR31	DR2R70QR	DRB1*1126,34,1344,1402,06,09,13,17,20,29,30,33
C08	DRM32	DR10	DR34	DR2R74L	DRB1*0820,1123,25,1313,18,1403,12,27
C09	DRM33	DR10	DR46	DR2R85?	DRB1*1106,21,1429
C10	DRM34	DR10	DR39	DR2R86G	DRB1*0302,05,09,14,17,1101,08-12,14,15,19,20,23,24,26-29,31-33,37,39,1302,03,05,07,12-14,21,23,25,26,29-31,33,34,36-39,41,45,1402,03,07,09,13,14,19,22,24,25,27,30,36
C11	DRM35	DR10	DR40	DR2R86V	DRB1*0301,03,04,06-08,10-13,15,16,0820,1102-04,06,07,13,16-18,21,25,34-36,38,1301,04,06,08-11,15,18-20,22,24,27,28,32,35,40,42-44,1401,05,06,08,12,16-18,20,21,23,26,29,32-35
C12	DRM36	DR07	DR21	DR2R37Y	DRB1*0801-08,10-15,17-19,1105,1317
D01	DRM37	DR07	DR18	DR2R37L	DRB1*1201-04,1206

Table 16

Tray	Mix	Primer S	Primer AS	label
D02	DRM38	DR07	DR23	DRB1*0817,1105,1201-06,1317
D03	DRM39	DR07	DR48	DRB1*0801-17,18,19,21,1404,11,15,28,31
D04	DRM40	DR07	DR26	DRB1*0801,03,05,06,10,12,14,16-19w
D05	DRM41	DR07	DR25	DRB1*0802,04,09,13,15,21,1105,1204,1317,1411,15
D06	DRM42	DR07	DR27	DRB1*1201-03,05,06
D07	DRM43	DR07	DR28	DRB1*1105,1204,1411
D08	DRM44	DR07	DR44	DRB1*0808,15,1404,28,31
D09	DRM45	DR07	DR45	DRB1*1201-03,05,06
D10	DRM46	DR07	DR29	DRB1*0801,02,04-09,11,16,17,21,1105,1202,1415
D11	DRM47	DR07	DR34	DRB1*0801-04,06-19,21,1415
D12	DRM48	DR07	DR46	DRB1*0812,1201,02,04-06,1428
E01	DRM49	DR07	DR39	DRB1*0801-03,05,07-09,11,13-19,21,1105
E02	DRM50	DR07	DR40	DRB1*0804,06,10,12,1201-06,1404,11,15,28,31
E03	DRM51	DR08	DR20	DRB1*0406,19-21
E04	DRM52	DR08	DR21	DRB1*0401-05,07-18,22-36,1122,1410
E05	DRM53	DR08	DR23	DRB1*0428,35,1122
E06	DRM54	DR08	DR26	DRB1*0405,09-12,17,24,28-30
E07	DRM55	DR08	DR25	DRB1*0401-04,06-08,13,14,16,18-23,25-27,31-36
E08	DRM56	DR08	DR28	DRB1*0415,1122
E09	DRM57	DR08	DR29	DRB1*0415,25,36,1122

Q3000-166666

Tray	Mix	Primer S	Primer AS	label	
E10	DRM58	DR08	DR30	DR2R67I	DRB1*0402,12w,14,18
E11	DRM59	DR08	DR70	DR2R70B	DRB1*0401,09,13,16,21,22,26,33-35
E12	DRM60	DR08	DR33	DR2R74E	DRB1*0403,06,07,11,17,20,22,27,1410
F01	DRM61	DR08	DR34	DR2R74L	DRB1*0412,18,25,31
F02	DRM62	DR08	DR39	DR2R86G	DRB1*0401,05,07-09,14,16,17,19-21,24,26,28-31,33-35,1122
F03	DRM63	DR08	DR40	DR2R86V	DRB1*0402-04,06,10-13,15,18,22,23,25,27,32,36,1410
F04	DRM64	DR11	DR17	DR2R37F	DRB1*0701,03,04
F05	DRM65	DR11	DR39	DR2R86G	DRB1*0701,03,04
F06	DRM66	DR01	DR27	DR2R57V	DRB1*0901
F07	DRM67	DR01	DR39	DR2R86G	DRB1*0901
F08	DRM68	DR03	DR20	DR2R37S	DRB3*0203
F09	DRM69	DR03	DR21	DR2R37Y	DRB1*1130
F10	DRM70	DR03	DR19	DR2R37N	DRB3*0206?
F11	DRM71	DR03	DR17	DR2R37F	DRB3*0301-03
F12	DRM72	DR03	DR26	DR2R57S	DRB3*0208
G01	DRM73	DR03	DR25	DR2R57D	DRB3*0107,0201-06,10-13
G02	DRM74	DR03	DR35	DR2R74Q	DRB3*0107,0201-03,05-13,0301,02
G03	DRM75	DR03	DR36	DR2R74R	DRB3*0101-06
G04	DRM76	DR03	DR39	DR2R86G	DRB3*0101-07,0202,03,05-13,0303
G05	DRM77	DR03	DR40	DR2R86V	DRB3*0201,04,0301,02

Tray	Mix	Primer S	Primer AS	label	
G06	DRM78	DR05	DR25	DR2R57D	DRB3*0107
G07	DRM79	DR05	DR39	DR2R86G	DRB3*0101-07
G08	DRM80	DR06	DR37	DR2R76G	DRB4*0102
G09	DRM81	DR06	DR38	DR2R81Y	DRB4*0101-04
G10	DRM82	DR06	DR40	DR2R86V	DRB4*0101-05
G11	DRM83	DR04	DR20	DR2R37S	NEG
G12	DRM84	DR04	DR16	DR2R37D	DRB5*0101,04-07,09
H01	DRM85	DR04	DR29	DR2R67F	DRB5*0101-05,08-10
H02	DRM86	DR04	DR32	DR2R71A	DRB5*0106,0202-04
H03	DRM87	DR04	DR34	DR2R74L	DRB5*0104
H04	DRM88	DR04	DR39	DR2R86G	DRB5*0101-05,07-10,0203
H05	DRM89	DR04	DR40	DR2R86V	DRB5*0106,0202,04,05
	Mix	P1		P2	
		15.0 ul		15.0 ul	

Table 5

ID		Location	
CI06	3'	HLA-C Ex3 243-263	Biotin
CI07	3'	HLA-C Ex3 243-263	Biotin
CI08	3'	HLA-B&C Ex3 195-213	Biotin
CI09	3'	HLA-C Ex4 234-251	Biotin
CI10	3'	HLA-C Ex3 258-275	Biotin
CI11	3'	HLA-C Ex3 195-213	Biotin
CI12	3'	HLA-C Ex4 31-49	Biotin
CI13	3'	HLA-C Ex3 134-151	Biotin
CI14	3'	HLA-B & C Ex3 18-36	Biotin
CI16	3'	HLA-C Ex4 4-23	Biotin
CI17	3'	HLA-C Ex4 4-23	Biotin
CI19	3'	HLA-C Ex3 25-42	Biotin
CI21	3'	HLA-ABC Ex3 216-233	Biotin
CI22	3'	HLA-A & C Ex 3 196-214	Biotin
CI23	3'	HLA-B & C Ex3 65-84	Biotin
CI24	3'	HLA-C Ex3 131-148	Biotin
CI28	3'	HLA-C Ex2 229-246	Biotin
CI29	3'	HLA-A Ex3 216-233	Biotin
CI30	3'	HLA-ABC Ex3 216-233	Biotin
CI31	3'	HLA-A Ex3 195-213	Biotin
CI32	3'	HLA-A Ex3 48-64	Biotin
CI35	3'	HLA-C Ex3 25-41	Biotin
CI36	3'	HLA-B & C Ex3 169-185	Biotin
CI44	3'	HLA-B Ex2 219-236	Biotin
CI55	3'	HLA-B Ex3 195-213	Biotin
CI56	3'	HLA-B & C Ex3 44-59	Biotin
CI57	3'	HLA-ABC Ex3 76-92	Biotin
CI58	3'	HLA-B & C Ex3 77-95	Biotin
CI59	3'	HLA-B Ex3 92-111	Biotin
CI60	3'	HLA-B Ex3 201-218	Biotin
CI61	3'	HLA-ABC Ex3 216-233	Biotin
CI62	3'	HLA-B Ex3 229-246	Biotin
CI63	3'	HLA-B Ex3 260-276	Biotin
CI64	3'	HLA-B Ex3 262-279	Biotin
CI65	3'	HLA-B & C Ex3 10-29	Biotin

CI66	3'	HLA-B Ex3 18-36	Biotin
CI67	3'	HLA-B Ex3 184-201	Biotin
CI68	3'	HLA-B & C Ex3 69-87	Biotin
CI69	3'	HLA-A & B Ex3 68-85	Biotin
CI70	3'	HLA-B Ex3 156-173	Biotin
CI71	3'	HLA-B Ex2 173-192	Biotin
CI72	3'	HLA-A & B Ex2 246-264	Biotin
CI73	3'	HLA-B Ex4 168-187	Biotin
CI74	3'	HLA-B Ex3 11-28	Biotin
CI75	3'	HLA-B Ex2 229-245	Biotin
CI76	3'	HLA-ABC Ex3 216-233	Biotin
CI79	3'	HLA-B Ex3 120-136	Biotin
CI82	3'	HLA-A & B Ex3 228-245	Biotin
CI84	3'	HLA-B Ex3 120-136	Biotin
CI86	3'	HLA-B Ex2 226-243	Biotin
CI90	3'	HLA-ABC Ex3 156-172	Biotin
CI91	3'	HLA-B Ex3 44-60	Biotin
CI95	3'	HLA-B Ex2 207-225	Biotin
CI96	3'	HLA-B Ex2 207-226	Biotin
CI98	3'	HLA-B & C EX3 69-87	Biotin
CI100	3'	HLA-ABC Ex3 216-233	Biotin
CI109	3'	HLA-A Ex3 80-100	Biotin
CI110	3'	HLA-A Ex3 212-229	Biotin
CI111	3'	HLA-A Ex3 105-123	Biotin
CI112	3'	HLA-A Ex3 71-88	Biotin
CI113	3'	HLA-A Ex3 110-128	Biotin
CI116	3'	HLA-C Ex3 25-41	Biotin
CI117	3'	HLA-C EX3 183-200	Biotin
CI118	3'	HLA-C Ex3 169-186	Biotin
CI124	3'	HLA-B & C Ex3 195-213	Biotin
CI125	3'	HLA-C Ex4 234-251	Biotin
CI126	3'	HLA-C Ex3 258-275	Biotin
CI127	3'	HLA-C Ex3 195-213	Biotin
CI128	3'	HLA-C Ex3 18-36	Biotin
CI129	3'	HLA-C Ex3 246-265	Biotin
CI131	3'	HLA-B & C Ex3 76-93	Biotin
CI132	3'	HLA-B Ex3 69-86	Biotin
CI133	3'	HLA-A Ex3 20-39	Biotin

CI136	3'	HLA-A Ex2 186-205	Biotin
CI137	3'	HLA-A Ex3 216-232	Biotin
CI140	3'	HLA-A & B 224-262	Biotin
CI143	3'	HLA-A Ex2 184-203	Biotin
CI145	3'	HLA-A Ex2 226-43	Biotin
CI146	3'	HLA-B	Biotin
CI149	3'	Internal Control	Biotin
C3R195G	3'	HLA-C Ex 3 195-213	Biotin
C3R195C	3'	HLA-C Ex3 195-213	Biotin
C3R076A	3'	HLA-C Ex3 76-93	Biotin
C3R076C	3'	HLA-C Ex3 76-93	Biotin
C3R076T	3'	HLA-C Ex3 76-93	Biotin
C3R075TA	3'	HLA-C Ex3 75-93	Biotin

Table 6

ID			PRIMER
DQ01	5'	Biotin	DQB 8V-1
DQ02	5'	Biotin	DQB 26G-1
DQ03	5'	Biotin	DQB 26La-1
DQ04	5'	Biotin	DQB 26Y-2
DQ08	5'	Biotin	DQB 55P-1
DQ13	5'	Biotin	DQB 71K-1
DR01	5'	Biotin	DR2S9-4
DR02	5'	Biotin	DR2S10G
DR03	5'	Biotin	DR2S10L-1
DR04	5'	Biotin	DR2S11D-2
DR05	5'	Biotin	DR2S11R-1
DR06	5'	Biotin	DR2S13C-2
DR07	5'	Biotin	DR2S13G-1
DR08	5'	Biotin	DR2S13H-2
DR09	5'	Biotin	DR2S13R-1
DR10	5'	Biotin	DR2S13S-2
DR11	5'	Biotin	DR2S14K-2
DR12	3'		DR2R17-1R
DR13	5'	Biotin	DR2S26L-3
DR14	5'	Biotin	DR2S26L-4
DR22	5'	Biotin	DR2S37YA-1
DR24	5'	Biotin	DR2S52B-3
DR85	5'	Biotin	DR2S11A
DR86	5'	Biotin	DR2S14b
	5'	Biotin	DPA - E (PC)

SEQUENCE LISTING

	1.	SEQ ID NO:1:C101	CCGAGTGAACCTGCGGAAA
	2.	SEQ ID NO:2:C102	TACTACAACCAGAGCGAGGA
5	3.	SEQ ID NO:3:C103	CACAGACTGACCGAGTGAG
	4.	SEQ ID NO:4:C104	AGTCCAAGAGGGGAGCCG
	5.	SEQ ID NO:5:C105	CCACTCCATGAGGTATTTCT
	6.	SEQ ID NO:6:C106	TCTTCTCCAGAAGGCACCAT
	7.	SEQ ID NO:7:C107	CAGGTCAGTGTGATCTCCA
10	8.	SEQ ID NO:8:C108	CCTCCAGGTAGGCTCTCCA
	9.	SEQ ID NO:9:C109	CAGCCCCTCGTGCTGCAT
	10.	SEQ ID NO:10:C110	CGCGCGCTGCAGCGTCTT
	11.	SEQ ID NO:11:C111	CCTCCAGGTAGGCTCTCAG
	12.	SEQ ID NO:12:C112	CTCAGGGTGAGGGGCTCT
15	13.	SEQ ID NO:13:C113	TGAGCCGCCGTGTCCGCA
	14.	SEQ ID NO:14:C114	GGTCGCAGCCATACATCCA
	15.	SEQ ID NO:15:C115	CCGCGGGTATGACCAGTC
	16.	SEQ ID NO:16:C116	GCGTCTCCTTCCCGTTCTT
	17.	SEQ ID NO:17:C117	AGCGTCTCCTTCCCATTCTT
20	18.	SEQ ID NO:18:C118	TCCGCGGGTATG ACCAGTA
	19.	SEQ ID NO:19:C119	GCCCCAGGTTCGCAGCCAA
	20.	SEQ ID NO:20:C120	ACAAGCGCCAGGCACAGG
	21.	SEQ ID NO:21:C121	GAGCCACTCCACGCACTC
	22.	SEQ ID NO:22:C122	CCCTCCAGGTAGGCTCTCT
25	23.	SEQ ID NO:23:C123	TCGTAGGCTAACTGGTCATG
	24.	SEQ ID NO:24:C124	CCGCCGTGTCCGCGGCA
	25.	SEQ ID NO:25:C125	TACAACCAGAGCGAGGCCA
	26.	SEQ ID NO:26:C126	ACAACCAGAGCGAGGCCG
	27.	SEQ ID NO:27:C127	ACGACACGCAGTTCGTGCA
30	28.	SEQ ID NO:28:C128	GCGCAGGTTCCGCAGGC
	29.	SEQ ID NO:29:C129	GAGCCACTCCACGCACCG
	30.	SEQ ID NO:30:C130	GAGCCACTCCACGCACGT
	31.	SEQ ID NO:31:C131	CCTCCAGGTAGGCTCTCTG

32. SEQ ID NO:32:C132
33. SEQ ID NO:33:C133
34. SEQ ID NO:34:C134
35. SEQ ID NO:35:C135
5 36. SEQ ID NO:36:C136
37. SEQ ID NO:37:C137
38. SEQ ID NO:38:C138
39. SEQ ID NO:39:C139
40. SEQ ID NO:40:C140
10 41. SEQ ID NO:41:C141
42. SEQ ID NO:42:C142
43. SEQ ID NO:43:C143
44. SEQ ID NO:44:C144
45. SEQ ID NO:45:C145
15 46. SEQ ID NO:46:C146
47. SEQ ID NO:47:C147
48. SEQ ID NO:48:C148
49. SEQ ID NO:49:C149
50. SEQ ID NO:50:C150
20 51. SEQ ID NO:51:C151
52. SEQ ID NO:52:C152
53. SEQ ID NO:55:C155
54. SEQ ID NO:56:C156
55. SEQ ID NO:57:C157
25 56. SEQ ID NO:58:C158
57. SEQ ID NO:59:C159
58. SEQ ID NO:60:C160
59. SEQ ID NO:61:C161
60. SEQ ID NO:62:C162
30 61. SEQ ID NO:63:C163
62. SEQ ID NO:64:C164
63. SEQ ID NO:65:C165
64. SEQ ID NO:66:C166
65. SEQ ID NO:67:C167

CCGCGGAGGAAGCGCCA
CCTACTCCATGAGGTATTTCTT
CCGGAGTATTGGGACCTGC
CCCCAGGTCGCAAGCCAG
CGCACGGGCCCGCCTCCA
GCGCCGTGGATAGAGCAA
GCCGCGAGTCCGAGGAC
ACCGGAACACACAGATCTG
ACCGGGAGACACAGATCTC
GGAGTATTGGGACCGGAAC
AACATGAAGGCCTCCGCG
GACCGGAACACACAGATCTT
TACCGAGAGAACCTGCGC
AGCAGGAGGGGCCGGA
GGGGAGCCCCGCTTCATT
CAGATCTACAAGGCCCAGG
CCATGAGGTATTTCTACACCG
GACCGGAACACACAGATCTA
CCGAGAGAGCCTGCGGGAA
ACCGAGAGAACCTGCGGAT
CGCCGCGAGTCCGAGAGA
CCTCCAGGTAGGCTCTGTC
GAGGAGGCGCCCGTCG
CTTGCCGTCGTAGGCGG
ATCCTTGCCGTCGTAGGCT
CGTTCAGGGCGATGTAATCT
CGTGCCCTCCAGGTAGGT
GAGCCACTCCACGCACTC
CCAGGTATCTGCGGAGCG
CCGCGCGCTCCAGCGTG
TACCAGCGCGCTCCAGCT
GCCATACATCCTCTGGATGA
CGTCGCAGCCATACATCAC
CTCTCAGCTGCTCCGCCT

	66. SEQ ID NO:68:C168	GTCGTAGGCGGACTGGTC
	67. SEQ ID NO:69:C169	TCGTAGGCGTCCTGGTGG
	68. SEQ ID NO:70:C170	CTCCAACCTTGCGCTGGGA
	69. SEQ ID NO:71:C171	GTGTGTTCCGGTCCCAATAT
5	70. SEQ ID NO:72:C172	CGCTCTGGTTGTAGTAGCG
	71. SEQ ID NO:73:C173	GCCCACTTCTGGAAGGTTCT
	72. SEQ ID NO:74:C174	CCATACATCGTCTGCCAA
	73. SEQ ID NO:75:C175	GCGCAGGTTCCGCAGGC
	74. SEQ ID NO:76:C176	GAGCCACTCCACGCACAG
10	75. SEQ ID NO:77:C177	GGGTACCCAGCAGGACGCT
	76. SEQ ID NO:78:C178	GAGACACAGAAGTACAAGCG
	77. SEQ ID NO:79:C179	GCCGCGGTCCAGGAGCT
	78. SEQ ID NO:80:C180	CGAGAGAGCCTGCGGAAC
	79. SEQ ID NO:81:C181	CGCGAGTCCGAGGATGGC
15	80. SEQ ID NO:82:C182	CAGGTATCTGCGGAGCCC
	81. SEQ ID NO:83:C183	CCACTCCCATGAGGTATTTCC
	82. SEQ ID NO:84:C184	GCGGCGGTCCAGGAGCG
	83. SEQ ID NO:85:C185	CCTCCAGGTAGGCTCTCAA
	84. SEQ ID NO:86:C186	GCAGGTTCCGCAGGCTCT
20	85. SEQ ID NO:87:C187	GGACCTGCGGACCCTGCT
	86. SEQ ID NO:88:C188	GGGAGCCCCGCTTCATCT
	87. SEQ ID NO:89:C189	CGCCACGAGTCCGAGGAA
	88. SEQ ID NO:90:C190	TCCCACTTGCGCTGGGT
	89. SEQ ID NO:91:C191	GGAGGAAGCGCCCGTCG
25	90. SEQ ID NO:92:C192	GAGCCTGCGGACCCTGCT
	91. SEQ ID NO:93:C193	CGAGTGGGCCTGCGGAAC
	92. SEQ ID NO:94:C194	GCTACGTGGACGACACGGCT
	93. SEQ ID NO:95:C195	CTCGGTCAGTCTGTGCCTT
	94. SEQ ID NO:96:C196	TCTCGGTAAGTCTGTGCCTT
30	95. SEQ ID NO:97:C197	TATTGGGACGAGGAGACAG
	96. SEQ ID NO:98:C198	CGTCGTAGGCGTACTGGTC
	97. SEQ ID NO:99:C199	CGACGCCGCGAGCCAGAA
	98. SEQ ID NO:100:CI100	GAGCCCGTCCACGCACTC
	99. SEQ ID NO:101:CI101	TCACAGACTGACCGAGCGAA

100. SEQ ID NO:102:CI102
 101. SEQ ID NO:103:CI103
 102. SEQ ID NO:104:CI104
 103. SEQ ID NO:105:CI105
 5 104. SEQ ID NO:106:CI106
 105. SEQ ID NO:107:CI107
 106. SEQ ID NO:108:CI108
 107. SEQ ID NO:109:CI109
 108. SEQ ID NO:110:CI110
 10 109. SEQ ID NO:111:CI111
 110. SEQ ID NO:112:CI112
 111. SEQ ID NO:113:CI113
 112. SEQ ID NO:114:CI114
 113. SEQ ID NO:115:CI115
 15 114. SEQ ID NO:116:CI116
 115. SEQ ID NO:117:CI117
 116. SEQ ID NO:118:CI118
 117. SEQ ID NO:119:CI119
 118. SEQ ID NO:120:CI120
 20 119. SEQ ID NO:121:CI121
 120. SEQ ID NO:122:CI122
 121. SEQ ID NO:123:CI123
 122. SEQ ID NO:124:CI124
 123. SEQ ID NO:125:CI125
 25 124. SEQ ID NO:126:CI126
 125. SEQ ID NO:127:CI127
 126. SEQ ID NO:128:CI128
 127. SEQ ID NO:129:CI129
 128. SEQ ID NO:130:CI130
 30 129. SEQ ID NO:131:CI131
 130. SEQ ID NO:132:CI132
 131. SEQ ID NO:133:CI133
 132. SEQ ID NO:134:CI134
 133. SEQ ID NO:135:CI135

ACGGAATGTGAAGGCCAG
 AGCGACGCCGCGAGCCA
 GGCCGGAGTATTGGGACGA
 GATAGAGCAGGAGAGGCCT
 TCACAGACTGACCGAGAGAG
 CCCGGCCCCGGCAGTGGA
 GTGGATAGAGCAGGAGGGT
 AGTTAATCCTTGCCGTCGTAA
 CACTCCACGCACGTGCCA
 AGCGCAGGTCCTCGTTCAA
 CCGTCGTAGGCGTGCTGT
 CCAAGAGCGCAGGTCCTCT
 ACACAGATCTACAAGACCAAC
 GGACCCGGGAGACACAGAAC
 CCCCAGGTCGCAGCCAC
 TCTCAGCTGCTCCGCCGT
 CTCACGGGGCCGCTCCA
 CCGAGTGAACCTGCGGAAA
 TACTACAACCAGAGCGAGGA
 CACGACTGACCGAGTGAG
 AGTCCAAGAGGGGAGCCG
 CCACTCCATGAGGTATTTCTC
 CCTCCAGGTAGGCTCTCCA
 CAGCCCCTCGTGCTGCAT
 CGCGCGCTGCAGCGTCTT
 CCTCCAGGTAGGCTTCAG
 GGTCGCAGCCAAACATCCA
 AGCGTCTCCTTCCCATTCTT
 TACCGAGAGAACCTGCGCA
 CCTTGCCGTCGTAGGCGA
 GTCGTAGGCGTCCTGGTC
 CCACGTCGCAGCCATACATT
 GCCGCGAGTTCGAGAGG
 ACCGAGAGAACCTGCGGAT

	134. SEQ ID NO:136:CI136	GCCTTCACATTCCGTGTGTT
	135. SEQ ID NO:137:CI137	AGCCCGTCCACGCACCG
	136. SEQ ID NO:138:CI138	CCACTCCATGAGGTATTTAC
	137. SEQ ID NO:139:CI139	CCTGCGCACCGCGCTCC
5	138. SEQ ID NO:140:CI140	CTCTGGTTGTAGTAGCGGA
	139. SEQ ID NO:141:CI141	GGGTACCGGCAGGACGCT
	140. SEQ ID NO:142:CI142	ACGGAAAGTGAAGGCCAG
	141. SEQ ID NO:143:CI143	CTTCACATTCCGTGTCTCCT
	142. SEQ ID NO:144:CI144	CACGCAGTTCGTGCGGTTT
10	143. SEQ ID NO:145:CI145	GCAGGGTCCCCAGGTCCA
	144. SEQ ID NO:146:CI146	GCTCTGGTTGTAGTAGCGGA
	145. SEQ ID NO:147:CI147	GACGACACGCTGTTTCGTGA
	146. SEQ ID NO:148:CI150	ACGTCGCAGCCGTACATG
	147. SEQ ID NO:149:C2F30T	TCCATGAAGTATTTACAT
15	148. SEQ ID NO:150:C2F32T	CATGAGGTATTTCTACACCGCT
	149. SEQ ID NO:151:C2F25A	CACTCCATGAGGTATTTCTGA
	150. SEQ ID NO:152:C2F25C	CACTCCATGAGGTATTTCTC
	151. SEQ ID NO:153:C2F32C	TGAGGTATTTCTACACCGCC
	152. SEQ ID NO:154:C3R195G	CCTCCAGGTAGGCTCTGTC
20	153. SEQ ID NO:155:C3R195C	CTCCAGGTAGGCTCTCCG
	154. SEQ ID NO:156:C34076A	CCTTGCCGTCGTAGGCGT
	155. SEQ ID NO:157:C34076C	CCTTGCCGTCGTAGGCGG
	156. SEQ ID NO:158:C3R076T	CCTTGCCGTCGTAGGCGA
	157. SEQ ID NO:159:C3R075TA	CCTTGCCGTCGTAGGCTA
25	158. SEQ ID NO:160:C2F216A	TACAAGCGCCAGGCACAGA
	159. SEQ ID NO:161:CI53	ATGATGTTGACCTTTCCAGGG
	160. SEQ ID NO:162:CI54	TTCTGTAACTTTTCATCAGTTGC
	161. SEQ ID NO:163:CI148	TGCCAAGTGGAGCACCCAA
	162. SEQ ID NO:164:CI149	GCATCTTGCTCTGTGCAGA
30	163. SEQ ID NO:165:CICptA1	ACGCCTACGACGGCAAGGATTACATCGCCC
	164. SEQ ID NO:166:CICptA2	GATGGAGCCGCGGTGGATAGAGCAAGGAGGG
	165. SEQ ID NO:167:CICptB1	CAGTTCGTGAGGTTTCGACAGCGACGCC
	166. SEQ ID NO:168:CICptB2	CTGCGCGGCTACTACAACCAGAGCGAGGCC
	167. SEQ ID NO:169:DQ01	TCC[CT]CGCAGAGGATTTCTGTG

	168. SEQ ID NO:170:DQ02	GGAGCGCGTGCGGGG
	169. SEQ ID NO:171:DQ03	ACGGAGCGCGTGCGTCT
	170. SEQ ID NO:172:DQ04	GGACGGAGCGCGTGCGTTA
	171. SEQ ID NO:173:DQ05	GTA CTCTCTCTCGGTTATAGATGTG
5	172. SEQ ID NO:174:DQ06	GATCTCTTCTCGGTTATAGATGC
	173. SEQ ID NO:175:DQ07	GTCGCTGTCGAAGCGCA
	174. SEQ ID NO:176:DQ08	TGACGCCGCTGGGGCC
	175. SEQ ID NO:177:DQ09	GCTGTTCCAGTACTCGGCGT
	176. SEQ ID NO:178:DQ10	GCTGTTCCAGTACTCGGCGCT
10	177. SEQ ID NO:179:DQ11	GCTGTTCCAGTACTCGGCAA
	178. SEQ ID NO:180:DQ12	CAACTCCGCCCCGGGTCCT
	179. SEQ ID NO:181:DQ13	GAAGGACATCCTGGAGAGGAA
	180. SEQ ID NO:182:DQ14	GGTCGTGCGGAGCTCCAACTG
	181. SEQ ID NO:183:DQ15	CACTCTCCTCTGCAGGATCCC
15	182. SEQ ID NO:184:DR01	CCCC[AC]CAGCACGTTTCTTGA
	183. SEQ ID NO:185:DR02	CCAGCACGTTTCTTGGAGG
	184. SEQ ID NO:186:DR03	[AC]CAGCACGTTTCTTGGAGCT
	185. SEQ ID NO:187:DR04	CACGTTTCTTGCAGCAGGA
	186. SEQ ID NO:188:DR05	CACGTTTCTTGGAGCTGCG
20	187. SEQ ID NO:189:DR06	CGTTTCTTGGAGCAGGCTAAGTG
	188. SEQ ID NO:190:DR07	CGTTTCTTGGAGTACTCTACGGG
	189. SEQ ID NO:191:DR08	ACGTTTCTTGGAGCAGGTAAAC
	190. SEQ ID NO:192:DR09	CGTTTCCTGTGGCAGCCTAAGA
	191. SEQ ID NO:193:DR10	CGTTTCTTGGAGTACTCTACGTC
25	192. SEQ ID NO:194:DR11	CGTTTCCTGTGGCAGGGTAAGTATA
	193. SEQ ID NO:195:DR12	GTTATGGAAGTATCTGTCCAGGT
	194. SEQ ID NO:196:DR13	CGGAGCGGGTGCGGTTG
	195. SEQ ID NO:197:DR14	ACGGAGCGGGTGCGGTTG
	196. SEQ ID NO:198:DR15	ACTCCTCCTGGTTATAGAAGTG
30	197. SEQ ID NO:199:DR16	GCTGTCGAAGCGCAAGTC
	198. SEQ ID NO:200:DR17	TCGCTGTCGAAGCGCACGA
	199. SEQ ID NO:201:DR18	GCTGTCGAAGCGCAGGAG
	200. SEQ ID NO:202:DR19	CGCTGTCGAAGCGCACGTT
	201. SEQ ID NO:203:DR20	GCTGTCGAAGCGCACGG

	202. SEQ ID NO:204:DR21	GCTGTCGAAGCGCACGTA
	203. SEQ ID NO:205:DR22	CGCTGTCGTAGCGCGCGT
	204. SEQ ID NO:206:DR23	TCCGTCACCGCCCCGGA
	205. SEQ ID NO:207:DR24	GGAGTACCGGGCGGTGAG
5	206. SEQ ID NO:208:DR25	CTGTTCCAGTACTCGGCAT
	207. SEQ ID NO:209:DR26	TGTTCCAGTACTCGGCGCT
	208. SEQ ID NO:210:DR27	CTGTTCCAGGACTCGGCGA
	209. SEQ ID NO:211:DR28	TCAGGCTGTTCCAGTACTCCT
	210. SEQ ID NO:212:DR29	CGCGCCTGTCTTCCAGGAA
10	211. SEQ ID NO:213:DR30	CCCGCTCGTCTTCCAGGAT
	212. SEQ ID NO:214:DR31	CACCGCGGCCCCGCCTCTG
	213. SEQ ID NO:215:DR32	CACCGCGGCCCCGCGC
	214. SEQ ID NO:216:DR33	TGCAATAGGTGTCCACCTC
	215. SEQ ID NO:217:DR34	TGCAGTAGGTGTCCACCAG
15	216. SEQ ID NO:218:DR35	GTGTCTGCAGTAATTGTCCACCTG
	217. SEQ ID NO:219:DR36	GTGTCTGCAGTAATTGTCCACCC
	218. SEQ ID NO:220:DR37	ATGTCTGCAGTAGGTGC
	219. SEQ ID NO:221:DR38	CTCTCCACCAACCCGTAGTTGTA
	220. SEQ ID NO:222:DR39	TGCACTGTGAAGCTCTCAC
20	221. SEQ ID NO:223:DR40	CTGCACTGTGAAGCTCTCCA
	222. SEQ ID NO:224:DR41	CCCCGTAGTTGTGTCTGCAA
	223. SEQ ID NO:225:DR42	GCAGTAGGTGTCCACCGC
	224. SEQ ID NO:226:DR43	GCAATAGGTGTCCACCTC
	225. SEQ ID NO:227:DR44	CCTTCTGGCTGTTCCCAGTG
25	226. SEQ ID NO:228:DR45	TCCTTCTGGCTGTTCCAGG
	227. SEQ ID NO:229:DR46	ACAGTGAAGCTCTCCACAG
	228. SEQ ID NO:230:DR47	CTCCGTCACCGCCCCGGA
	229. SEQ ID NO:231:DR48	CTCCGTCACCGCCCCGGTA
	230. SEQ ID NO:232:DR49	CTCCTCCTGGTTATGGAAGTA
30	231. SEQ ID NO:233:DR50	CTCCTCCTGGTTATGGAAGTA
	232. SEQ ID NO:234:DR51	TCGCTGTCGAAGCGCACGTCG
	233. SEQ ID NO:235:DR52	CGCTGTCGAAGCGCAACGGAT
	234. SEQ ID NO:236:DR53	CGCTGTCGAAGCGCACGTCG
	235. SEQ ID NO:237:DR54	TCGCTGTCGAAGCGCAGGA

	236. SEQ ID NO:238:DR55	TCGCTGTCTGAAGCGCACGA
	237. SEQ ID NO:239:DR56	ACGTCGCTGTCTGAAGCGCAG
	238. SEQ ID NO:240:DR57	TCACCGCCCGGTACTCCCT
	239. SEQ ID NO:241:DR58	CCAAGCTCCGTACCGCCT
5	240. SEQ ID NO:242:DR59	CCGCCCCAGCTCCGTCTG
	241. SEQ ID NO:243:DR60	GCTGTTCCAGTGCTCCGCAG
	242. SEQ ID NO:244:DR61	GCTGTTCCAGTGCTCCGCAT
	243. SEQ ID NO:245:DR62	GGCTGTTCCAGTACTCAGCG
	244. SEQ ID NO:246:DR63	GCTGTTCCAGTACTCGGCGA
10	245. SEQ ID NO:247:DR64	TTCTGGCTGTTCCAGTACTCA
	246. SEQ ID NO:248:DR65	CCGCCTCTGCTCCAGGAG
	247. SEQ ID NO:249:DR66	CCGCGCCTGCTCCAGGAT
	248. SEQ ID NO:250:DR67	ACCGCGGCGCGCCTGTCT
	249. SEQ ID NO:251:DR68	CCGCGGCCCCGCGCCTGC
15	250. SEQ ID NO:252:DR69	CACCGCGGCGCGCCTGTT
	251. SEQ ID NO:253:DR70	CACCTCGGCCCCGCCTCC
	252. SEQ ID NO:254:DR71	GTCCACCGCGGCGCGCGT
	253. SEQ ID NO:255:DR72	TGTCCACCGCGGCCCCGCT
	254. SEQ ID NO:256:DR73	TCCACCGCGGCCCCGCGC
20	255. SEQ ID NO:257:DR74	TCCACCGCGGCCCCGCTC
	256. SEQ ID NO:258:DR75	TGTCCACCGCGGCCCCGCT
	257. SEQ ID NO:259:DR76	TAGGTGTCCACCGCGGCG
	258. SEQ ID NO:260:DR77	GCGCCACCTGTGGATGACG
	259. SEQ ID NO:261:DR78	TCTGCAGTAATTGTCCACCTG
25	260. SEQ ID NO:262:DR79	GTCTGCAATAGGTGTCCACCT
	261. SEQ ID NO:263:DR80	CTGCAGTAGTTGTCCACCCG
	262. SEQ ID NO:264:DR81	CCGTAGTTGTATCTGCAGTAGT
	263. SEQ ID NO:265:DR82	CCGTAGTTGTGTCTGCAGTAGT
	264. SEQ ID NO:266:DR83	CCCGTAGTTGTGTCTGCAGTAAT
30	265. SEQ ID NO:267:DR84	CCCGTAGTTGTGTCTGCACAC
	266. SEQ ID NO:268:DR85	CAGCACGTTTCTTGGAGCTGT
	267. SEQ ID NO:269:DR86	TTCTTGTGGCAGCTTAAGTTTGA
	268. SEQ ID NO:270:DPA-E(PC)	GATCCCCCTGAGGTGACCGTG
	269. SEQ ID NO:271:DPA-F(PC)	CTGGGCCCGGGGGTCATGGCC

